Clinical trial register · France

Clinical Trials in Lyon, 2026

Every study on the ClinicalTrials.gov registry that lists a site in France and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 9697 matching records held by the registry are in this view. Synced 26 Oct 2026, 03:20 UTC

9697

Studies in scope

all four open statuses

6025

Recruiting now

open to new participants

1033

Lead sponsors

across recruiting studies

Top sites

Paris 2821 Lyon 1392 Bordeaux 1389 Marseille 1285 Lille 1282

Trials with a site in Lyon

Status

Study

Lead sponsor

Phase

Enrol

Sites in France

Start

Active, closed

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

NCT06608927Metastatic Pancreatic Ductal Adenocarcinoma

DrugsQuemliclustat·Nab-paclitaxel·Gemcitabine

Arcus Biosciences, Inc.

Phase 3

610

Dijon, Lille, Lyon, Poitiers, Villejuif

2024-12-13

Recruiting

Study of Post-operative Complications After Laparoscopic Outpatient Nephrectomy

NCT06532422Kidney Cancer

GCS Ramsay Santé pour l'Enseignement et la Recherche

Observational

Lyon

2024-12-13

Active, closed

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

NCT06691984Metastatic Castration-resistant Prostate Cancer

DrugsXaluritamig·Cabazitaxel·Abiraterone·Enzalutamide

Amgen

Phase 3

707

Bordeaux, Clermont-Ferrand, La Tronche, Le Mans, Lille, Lyon, Marseille, Nice

2024-12-09

Recruiting

Evaluation of the Reproducibility of a Fatigability Test Fitted to Patients With Spinal Muscular Atrophy

NCT06562283Spinal Amyotrophy, Infantile Spinal Muscular Atrophy, Juvenile Spinal Muscular Atrophy

Centre Hospitalier Universitaire de Saint Etienne

Not applicable

Saint-Etienne, Lyon, Paris

2024-12-06

Recruiting

MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)

NCT06534437Non-Hodgkin Lymphoma, B-cell

DrugGlofitamab

Ryvu Therapeutics SA

Phase 2

178

Le Mans, Lille, Limoges, Lyon, Montpellier, Paris, Pessac

2024-12-05

Recruiting

Natural History Study of Children With LAMA2-related Dystrophies

NCT06354790Merosin Deficient Congenital Muscular Dystrophy

Institut de Myologie, France

Observational

Garches, Lyon, Montpellier, Paris

2024-12-05

Recruiting

Nosocomial Respiratory Virus Infection

NCT06643039Nosocomial Infections

DrugNasopharyngeal swab

Hospices Civils de Lyon

Not applicable

1,000

Bordeaux, Dijon, Lyon, Paris

2024-12-05

Recruiting

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

NCT06382948Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, ESR1 Gene Mutation

DrugsElacestrant·Everolimus

MedSIR

Phase 3

300

Bordeau, Bordeaux, Dijon, Limoges, Lyon, Marseille, Paris, Plérin

2024-12-05

Recruiting

Evaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology

NCT06392997Gynecologic Disease, Gynecologic Cancer, Endometriosis, Ovarian Cancer

ZIWIG

Observational

2,500

Angers, Bordeaux, Caen, Dijon, Lyon, Neuilly-sur-Seine, Rennes, Rouen

2024-12-05

Recruiting

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

NCT06472245Patients With Non-Small Cell Lung Cancer

DrugsTedopi·Docetaxel

OSE Immunotherapeutics

Phase 3

363

Toulon, Strasbourg, Bron, Lyon, Marseille, Besançon, Brest, Mulhouse

2024-12-03

Active, closed

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)

NCT06685757Antibody-mediated Rejection

DrugFelzartamab

Biogen

Phase 3

132

Bordeaux, La Tronche, Lyon, Toulouse

2024-12-03

Recruiting

Mind-wandering and Predictive Processes in Narcolepsy: a Putative Mechanism Through Covert REM Intrusions

NCT06457945Narcolepsy Type 1, Hypersomnolence, Idiopathic Hypersomnia

Hospices Civils de Lyon

Not applicable

180

Lyon

2024-12-03

Recruiting

Characterization of the IFN-I Response in Subjects Who Experienced Severe or Mild Forms of COVID-19

NCT06703034COVID-19

Hospices Civils de Lyon

Not applicable

134

Lyon

2024-12-02

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

NCT06627647Non-squamous Non-small Cell Lung Cancer

DrugsRilvegostomig·Pemetrexed·Keytruda·Cisplatin

AstraZeneca

Phase 3

1,160

Avignon, La Rochelle, Lyon, Nîmes, Rennes, Strasbourg, Suresnes, Toulon

2024-11-27

Recruiting

Use of a Freeze-dried Amniotic Membrane Post Crosslinking in Subjects With Progressive Keratoconus

NCT06450470Progressive Keratoconus

TBF Genie Tissulaire

Phase 3

116

Brest, Lyon, Marseille, Montpellier, Nantes, Paris, Saint-Priest-en-Jarez, Strasbourg

2024-11-25

Recruiting

ADDICTOlogical Intervention in LIVEr Transplantation Recipients

NCT06472973Alcohol Associated Liver Disease, Liver Transplantation

University Hospital, Montpellier

Not applicable

720

Besançon, Bordeaux, Clermont-Ferrand, Dijon, Lille, Lyon, Marseille, Montpellier

2024-11-21

Recruiting

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

NCT06690775Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Endometrioid Ovarian Cancer

DrugsTORL-1-23·Pegfilgrastim

TORL Biotherapeutics, LLC

Phase 2

230

Lyon, Saint-Herblain, Villejuif

2024-11-20

Active, closed

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

NCT06578247Leukemia

DrugQuizartinib

Daiichi Sankyo

Phase 3

700

Angers, Caen, La Tronche, Le Chesnay, Lille, Lyon, Marseille, Nantes

2024-11-19

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

NCT06692738Non-small Cell Lung Cancer

DrugsRilvegostomig·Nab-paclitaxel·Keytruda·Paclitaxel

AstraZeneca

Phase 3

1,160

Avignon, La Rochelle, Lyon, Nîmes, Rennes, Strasbourg, Suresnes, Toulon

2024-11-18

Recruiting

Contribution of Multicenter Expertise and Deformable Fusion Software for Re-irradiations With Curative Intent

NCT06668038Re-irradiation, Radiotherapy

Centre Leon Berard

Not applicable

100

Angers, Bourg-en-Bresse, Dijon, Grenoble, Lyon, Marseille, Nice, Saint-Herblain

2024-11-15

Not yet open

Assessing the Ompact of Neutral Pelvic Positioning on Bone Repositioning Quality in Pelvic Radiotherapy Patients

NCT06687200Radiotherapy, Repositonning Pelvic, Neutral Pelvic Positioning

Centre Leon Berard

Not applicable

200

Lyon, Nancy, Rennes, Saint-Herblain

2024-11-15

Recruiting

First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors

NCT06644755Solid Tumors, Sarcoma

Daiichi Sankyo

Phase 1

150

Lyon

2024-11-14

Recruiting

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

NCT06632457Metabolic Dysfunction Associated Steatohepatitis

Boehringer Ingelheim

Phase 3

1,590

Amiens, Angers, Clichy, Créteil, Dijon, Le Chesnay, Lille, Lyon

2024-11-12

Active, closed

Study To Assess Effectiveness and Adverse Events of Foscarbidopa/ Foslevodopa in Adult Participants With Advanced Parkinson Disease in Real Life Setting

NCT06639620Advanced Parkinson Disease

AbbVie

Observational

250

Strasbourg, Clermont-Ferrand, Lyon, Marseille, Saint-Brieuc, Besançon, Brest, Limoges

2024-11-12

Active, closed

A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

NCT06537414Chronic Hepatitis B Virus Infection, Hepatitis B

DrugBepirovirsen

GlaxoSmithKline

Phase 2

283

Clichy, Créteil, Limoges, Lyon, Marseille

2024-11-11

Recruiting

Inertial Sensors for Obstetrical Walking Epidural Tracking

NCT06471790Pregnancy Related, Epidural; Anesthesia, Headache, Labor Complication

Hospices Civils de Lyon

Observational

Lyon

2024-11-11

Recruiting

Anti-GD2 ADC M3554 in Advanced Solid Tumors

NCT06641908Advanced Solid Tumor

EMD Serono Research & Development Institute, Inc.

Phase 1

Bordeaux, Lille, Lyon, Nice

2024-11-08

Active, closed

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

NCT06676319Asthma

DrugsBudesonide/Formoterol·Lunsekimig

Sanofi

Phase 2

556

Amiens, Lyon, Montpellier, Paris, Pessac, Strasbourg, Toulouse

2024-11-07

Recruiting

Study of IMC-P115C in Advanced PRAME-Positive Cancers

NCT07156136PRAME Positive, Cancer, HLA-A*02:01-positive

Immunocore Ltd

Phase 1

140

Lyon, Toulouse, Villejuif

2024-11-07

Recruiting

A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)

NCT05582993Von Willebrand Disease (VWD)

DrugsAdvate·Vonicog Alfa

Takeda

Phase 3

Lille, Lyon

2024-11-06

Recruiting

Microbiota and Carcinogenesis of Small-intestine Neuroendocrine Tumors

NCT06624865Small-intestine Neuroendocrine Tumors

Hospices Civils de Lyon

Observational

Lyon

2024-11-05

Recruiting

Evaluation of the Treatment of Arthritis and the Correction of Bone Alignment Default of the Toes With Lync

NCT06888934Arthritis Foot, Bone Alignment Defaults

Novastep

Not applicable

Lyon, Mâcon, Nancy, Perpignan, Rillieux-la-Pape

2024-11-04

Active, closed

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

NCT06596694Gastrointestinal Cancer

DrugPatritumab deruxtecan

Merck Sharp & Dohme LLC

Phase 1/2

180

Lyon, Clichy, Rennes

2024-11-03

Recruiting

Describe the Progression of Inflammatory Orbitopathy and the Biological Progression of Patients Receiving Second-line Treatment

NCT07117981Basedow Disease

Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts

Observational

100

Paris, Caen, Lyon, Marseille, Montpellier, Nîmes, Rennes, Strasbourg

2024-11-01

Recruiting

Acquisition of Full Oral Feeding and Further Oral Disorders in Extremely Preterm Infants

NCT06648083Oral Disorders

Hospices Civils de Lyon

Observational

170

Lyon

2024-11-01

Recruiting

Ziconotide for Non-cancer Pain by Intrathecal Administration

NCT06541184Pain, Chronic

DrugZiconotide

ESTEVE Pharmaceuticals SAS

Observational

Aubagne, Bron, Caen, La Roche-sur-Yon, Laon, Lille, Lorient, Lyon

2024-10-30

Recruiting

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

NCT06541704Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)

DrugsCemdisiran·Pozelimab

Regeneron Pharmaceuticals

Phase 3

975

Nice, Marseille, Poitiers, Toulouse, Créteil, Dijon, Lille, Lyon

2024-10-30

Active, closed

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

NCT06655896Scleroderma, Diffuse

DrugsRapcabtagene autoleucel·Rituximab

Novartis Pharmaceuticals

Phase 2

Bordeaux, Dijon, Lille, Lyon, Montpellier, Paris, Rennes, Strasbourg

2024-10-29

Recruiting

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

NCT06625775Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors

DrugsBBO-10203·Ribociclib·Folfox·Fulvestrant

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Phase 1

392

Montpellier, Saint-Cloud, Saint-Herblain, Bordeaux, Lyon, Villejuif

2024-10-29

Active, closed

A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

NCT06413706Glioma

DrugsAbemaciclib·Temozolomide

Eli Lilly and Company

Phase 2

Bordeaux, Lille, Lyon, Marseille, Paris, Villejuif

2024-10-25

Recruiting

Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

NCT06358573Triple-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer

DrugINT230-6

Swiss Cancer Institute

Phase 2

Lyon

2024-10-24

Active, closed

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor

Drugs5Fluorouracil·Leucovorin·Irinotecan·Cetuximab

Eli Lilly and Company

Phase 1

750

Lyon

2024-10-21

Recruiting

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

NCT06623422Carcinoma, Non-Small-Cell Lung

DrugsIntismeran autogene·Paraplatin·Taxol·Pemetrexed

Merck Sharp & Dohme LLC

Phase 3

680

Caen, Tours, Besançon, Saint-Herblain, Lille, Lyon, Paris, Villejuif

2024-10-21

Recruiting

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

NCT06662786Colorectal Neoplasms

DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Erbitux·Irinotecan

Janssen Research & Development, LLC

Phase 3

1,000

Avignon, Lille, Lyon, Montpellier, Nantes, Paris, Pessac, Poitiers

2024-10-18

Recruiting

Perioperative Hemostasis Management in Liver Transplantation

NCT06257407Liver Transplant; Complications

Société Française d'Anesthésie et de Réanimation

Observational

1,200

Besançon, Clermont, Clichy, Grenoble, Lille, Lyon, Marseille, Montpellier

2024-10-17

Recruiting

Deciphering the Interactions Between Food Intake, Sleepiness, and Nighttime Sleep Quality in Patients With Type 1 Narcolepsy and Idiopathic Hypersomnia

NCT06484348Narcolepsy Type 1, Idiopathic Hypersomnia

Hospices Civils de Lyon

Not applicable

Clermont-Ferrand, Lyon

2024-10-16

Active, closed

Streamlined Geriatric and Oncological Evaluation Based On IC Technology

NCT05720910Breast Cancer, Comorbidities and Coexisting Conditions, Lung Cancer, Colorectal Cancer

Institut Bergonié

Not applicable

720

Bayonne, Bordeaux, Dinan, La Roche-sur-Yon, Lyon, Mougins, Nice, Paris

2024-10-15

Recruiting

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

NCT06632444Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis

Boehringer Ingelheim

Phase 3

1,800

Amiens, Angers, Clichy, Créteil, Dijon, Le Chesnay, Lille, Lyon

2024-10-14

Recruiting

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

NCT06581432Solid Tumours

DrugZongertinib

Boehringer Ingelheim

Phase 2

588

Bordeaux, Dijon, Lyon, Marseille, Poitiers, Villejuif

2024-10-11

Active, closed

Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)

NCT05417789TGCT

DrugEmactuzumab

SynOx Therapeutics Limited

Phase 3

128

Bordeaux, Saint-Herblain, Paris, Lyon, Lille, Toulouse

2024-10-09

Recruiting

Efficacy of INM004 in Children With STEC-HUS

NCT06389474Hemolytic-Uremic Syndrome

Inmunova S.A.

Phase 3

220

Bordeaux, Lyon, Montpellier, Nantes, Paris, Rouen

2024-10-05

Recruiting

The Prevalence of the Aortic to Radial Pressure Gradient in States of Shock, Outside the Context of Cardiac Surgery, a Prospective Study

NCT06460519Shock

Hospices Civils de Lyon

Observational

180

Bron, Clermont-Ferrand, Lyon

2024-10-03

Recruiting

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

NCT06545955Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

DrugsNadofaragene Firadenovec·Docetaxel·Gemcitabine·Pembrolizumab

Ferring Pharmaceuticals

Phase 3

250

Clermont-Ferrand, Lyon, Toulouse, Nantes, Bordeaux, Nîmes, Paris

2024-10-01

Not yet open

Ability of Rotator Cuff Muscle Strength Levels, Assessed by Isokinetic Dynamometry, to Predict Return to Sport After Shoulder Stabilization Surgery by Open Latarjet Procedure

NCT06602713Latarjet, Shoulder Injuries, Rotator Cuff Injuries

GCS Ramsay Santé pour l'Enseignement et la Recherche

Not applicable

210

Lyon

2024-10-01

Recruiting

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

NCT06510374Intermediate Risk Non-Muscle Invasive Bladder Cancer

DrugNadofaragene Firadenovec

Ferring Pharmaceuticals

Phase 3

454

Clermont-Ferrand, Toulouse, Nantes, Bordeaux, Rouen, Nîmes, Lyon, Paris

2024-10-01

Not yet open

PAthwAy of Dyspneic patIent in Emergency in France

NCT06509854Acute Dyspnea

Pr. Nicolas GIRERD

Observational

89,700

Besançon, Dijon, Lyon, Nancy

2024-09-30

Recruiting

R-GASTIM- Study of Gastric Cancer Operable

NCT07787052Gastric Cancers

Centre Leon Berard

Observational

Lyon

2024-09-30

Recruiting

A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

NCT06551142Neoplasms

DrugsRis-Rez·Tarlatamab·Dostarlimab·Cetuximab

GlaxoSmithKline

Phase 1

845

Bordeaux, Lyon, Villejuif

2024-09-30

Active, closed

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

NCT06473779Severe Asthma

AstraZeneca

Phase 3

310

Créteil, La Tronche, Lyon, Marseille, Montpellier, Strasbourg

2024-09-30

Recruiting

Type 2 DIAbeTes With NAFLD: innOvative Biomarkers of Disease progressioN and clInical outComes

NCT06567990Metabolic Dysfunction-Associated Liver Disease

Hospices Civils de Lyon

Not applicable

500

Dijon, Lyon, Nantes, Pierre-Bénite

2024-09-25

Active, closed

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

NCT06525220Head and Neck Squamous Cell Carcinoma

DrugsPetosemtamab·Pembrolizumab

Merus B.V.

Phase 3

699

Bordeaux, Le Mans, Lille, Lyon, Marseille, Montpellier, Nice, Paris

2024-09-25

Recruiting

Study on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years With Advanced Ovarian Cancer

NCT06572735Ovarian Cancer

DrugBlood sampling

Hospices Civils de Lyon

Observational

Amiens, Bron, Clermont-Ferrand, Creil, Dijon, Lyon, Paris, Pierre-Bénite

2024-09-24

Active, closed

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06497556Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer

DrugsDivarasib·Adagrasib·Sotorasib

Hoffmann-La Roche

Phase 3

338

Brest, Bron, Lille, Lyon, Montpellier, Nice, Paris, Pessac

2024-09-23

Recruiting

European Registry of Next Generation Imaging in Advanced Prostate Cancer

NCT06866782Prostate Cancer, Advanced Prostate Cancer, Metastatic Prostate Cancer (mPC)

Fundacio Puigvert

Observational

600

Lille, Lyon, Paris

2024-09-17

Recruiting

Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

NCT06567015Non-small Cell Lung Cancer (NSCLC)

Pierre Fabre Medicament

Phase 1/2

171

Lyon, Marseille, Saint-Herblain, Toulouse, Villejuif

2024-09-17

Recruiting

Comparison of Two Antibiotic Regimens for the Treatment of Early Airways Infection With PA in Adults With Bronchiectasis

NCT06368804Bronchiectasis

Centre Hospitalier Intercommunal Creteil

Phase 2

196

Amiens, Bordeaux, Brest, Cergy-Pontoise, Créteil, Lyon, Marseille, Nantes

2024-09-15

Active, closed

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer

DrugsLeucovorin·Irinotecan·Cetuximab·Adrucil

Eli Lilly and Company

Phase 1

630

Lyon, Marseille, Toulouse, Villejuif

2024-09-12

Active, closed

Efficacy of a Systematic Referral to Palliative Care of Patients Who Need for Palliative Care During an Unscheduled Visit in Comprehensive Anticancer Centers

NCT06150027Cancer, Emergencies

Centre Leon Berard

Not applicable

240

Lyon, Montpellier, Paris, Saint-Cloud, Vandœuvre-lès-Nancy, Villejuif

2024-09-12

Recruiting

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

NCT06496581Prostate Cancer Metastatic

UNICANCER

Phase 3

500

Angers, Bordeaux, Brest, Caen, Créteil, Dijon, Grenoble, Lyon

2024-09-12

Active, closed

Evaluation of the Effect of Lomitapide Treatment on Major Adverse Cardiovascular Events (MACE) in Patients With Homozygous Familial Hypercholesterolemia

NCT06832371Homozygous Familial Hypercholesterolemia (HoFH), Major Adverse Cardiovascular Events (MACE), Dyslipidemia

Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)

Observational

Lille, Lyon, Marseille, Paris, Strasbourg

2024-09-09

Recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

NCT06476808High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC), Non-small Cell Lung Cancer (NSCLC)

Bristol-Myers Squibb

Phase 1

240

Bordeaux, Villejuif, Lyon

2024-09-06

Active, closed

Diagnostic and Management of Hand Infection.

NCT06630988Hand Infections, Including Whitlows, Tendinous Infections, Septic Arthritis

Hospices Civils de Lyon

Observational

1,400

Lyon

2024-09-01

Not yet open

Efficacy and Tolerance of Abacavir/Lamivudine Treatment in Patients With Systemic Lupus Erythematosus

NCT06356740Systemic Lupus Erythematosus

DrugBlood sample

Hospices Civils de Lyon

Phase 2

Bordeaux, Bron, Clermont-Ferrand, Grenoble, Lille, Lyon, Paris, Pierre-Bénite

2024-09-01

Active, closed

A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients

NCT06540391Melanoma

DrugsVancomycin·Keytruda·Pembrolizumab

Microbiotica Ltd

Phase 1

Dijon, Lille, Lyon, Marseille, Pierre-Bénite

2024-08-28

Recruiting

Ultra-portable Ultrasound vs. Standard Ultrasound to Help Place a Peripheral Catheter in Patients at Risk of Difficult Puncture

NCT06296264IV Line Placement With Ultrasound

Centre Hospitalier Saint Joseph Saint Luc de Lyon

Not applicable

250

Lyon

2024-08-27

Recruiting

Evaluating the Safety and Efficacy of the "HIFU" High-intensity Focused Ultrasound Treatment of Benign Prostatic Hyperplasia;

NCT06601179Benign Prostatic Hyperplasia

EDAP TMS S.A.

Not applicable

100

Besançon, Bordeaux, Lille, Lyon, Martigues, Suresnes, Toulon, Toulouse

2024-08-23

Recruiting

Contrast-enhanced Spectral Mammography (CESM) Early Quantitative Evaluation of Tumoral Response and Pathologic Complete Response Prediction for Localized Breast Cancer Treated by Neoadjuvant Chemotherapy

NCT06299202Breast Cancer

Hospices Civils de Lyon

Not applicable

100

Lyon

2024-08-23

Recruiting

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma

DrugZilovertamab vedotin

Merck Sharp & Dohme LLC

Phase 1/2

Bordeaux, Lyon, Nantes, Marseille, Villejuif

2024-08-16

Recruiting

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

NCT06467357Biliary Tract Cancer

DrugsRilvegostomig·Trastuzumab deruxtecan·Durvalumab·Gemcitabine

AstraZeneca

Phase 3

620

Brest, Clichy, Dijon, Lille, Lyon, Marseille, Montpellier, Pessac

2024-08-12

Recruiting

Assessment the sExual Quality of Life in Breast Cancer Patients Receiving oncoSexology Supportive Care on Proactive Versus On-request

NCT06415266Breast Cancer

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

264

Saint-Herblain, Vandœuvre-lès-Nancy, Lyon, Montpellier, Nice, Nîmes, Paris, Toulouse

2024-08-09

Active, closed

A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME

NCT06571045Diabetic Macular Edema (DME)

DrugsRemigromig·Lucentis·Ranibizumab

EyeBiotech Ltd.

Phase 2/3

984

Dijon, Créteil, Lyon, Marseille, Paris, Saint-Cyr-sur-Loire

2024-08-07

Recruiting

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

NCT06380751Advanced Breast Cancer

DrugsSaruparib·Camizestrant·Exemestane·Anastrozole

AstraZeneca

Phase 3

788

Angers, Besançon, Lille, Lyon, Marseille, Paris, Rouen, Saint-Herblain

2024-08-01

Active, closed

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

NCT06440967Hot Flashes

DrugsFezolinetant·Tamoxifen

Astellas Pharma Global Development, Inc.

Phase 3

982

Angers, Bayonne, Bordeaux, Caen, Dijon, Le Mans, Lille, Lyon

2024-07-31

Recruiting

HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life

NCT05373264ADPKD

DrugHydrochlorothiazide

University Medical Center Groningen

Phase 3

300

Bordeaux, Brest, Lyon, Nancy, Paris

2024-07-31

By invitation

Long-term Safety and Tolerability of BHV-7000

NCT06443463Focal Epilepsy

DrugOpakalim

Biohaven Therapeutics Ltd.

Phase 2

660

Strasbourg, Dijon, Toulouse, Montpellier, Tours, Nancy, Lille, Lyon

2024-07-30

Recruiting

Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis

NCT05841758Sarcoidosis, Pulmonary

DrugHydroxychloroquine

Hospices Civils de Lyon

Phase 4

140

Avignon, Bobigny, Créteil, Dijon, Lille, Limoges, Lyon, Montpellier

2024-07-30

Active, closed

A Study of GR1014 Cutaneous Gel for the Prevention of Skin Reactions Caused by Radiation Therapy for Breast Cancer

NCT07192588Radiodermatitis; Acute

Graegis Pharmaceuticals Ltd

Phase 2

273

Bordeaux, Lyon, Villejuif

2024-07-26

Recruiting

Intra-Hepatic Microbiota in Alcoholic Hepatitis

NCT06307964Cirrhosis, Alcoholic Liver Disease, Alcoholic Hepatitis

Hospices Civils de Lyon

Observational

Lyon

2024-07-23

Recruiting

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

NCT06362252Extensive Stage-small Cell Lung Cancer

DrugsIfinatamab Deruxtecan·Atezolizumab·Carboplatin

Daiichi Sankyo

Phase 1/2

123

Lille, Lyon, Marseille, Paris, Rennes, Saint-Herblain, Suresnes, Villejuif

2024-07-22

Recruiting

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

NCT06252649Metastatic Colorectal Cancer

DrugsSotorasib·Bevacizumab-awwb·Panitumumab·Mvasi

Amgen

Phase 3

450

Clermont-Ferrand, Créteil, Dijon, Lyon, Montpellier, Nice, Paris, Pessac

2024-07-17

Recruiting

Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer

NCT06439888Oligometastatic Disease, Solid Tumor, Adult

DrugsVesanoid·Tretinoin·All-trans retinoic acid

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2

Lyon, Villejuif

2024-07-11

Recruiting

A New Ultrasound Score for Swallowing Disorders Diagnosis in Difficult-to-wean Tracheostomised Patients

NCT06630013Deglutition Disorders

Hopital Forcilles

Observational

114

Beuvry, Dijon, Lyon, Férolles-Attilly

2024-07-09

Recruiting

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen

DrugIvosidenib

Servier Bio-Innovation LLC

Phase 3

136

Bordeaux, Lille, Lyon, Marseille, Paris, Saint-Herblain, Strasbourg, Toulouse

2024-07-09

Recruiting

Efficacy of a Mixed Distancial Neuropsychological Rehabilitation Program in Patients With Grade 2 or 3 Diffuse Glioma

NCT06468176Glioma, Malignant

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

187

Montpellier, Amiens, Bordeaux, Lyon, Marseille, Nancy, Nîmes, Toulouse

2024-07-05

Recruiting

A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)

NCT06431594Solid Tumors, Neoplasms

DrugMocertatug rezetecan

GlaxoSmithKline

Phase 1

675

Lyon, Saint-Herblain, Villejuif

2024-07-02

Active, closed

Transorb™ Self-Gripping Resorbable Mesh in High-risk Subjects Undergoing Open Repair of Ventral Hernia

NCT06449378Hernia, Hernia, Ventral, Hernia, Abdominal, Hernia Abdominal Wall

Medtronic - MITG

Not applicable

163

Colombes, Lille, Lyon, Reims, Rouen, Strasbourg

2024-07-02

Active, closed

A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus

NCT06015737Cutaneous Lupus Erythematosus

AstraZeneca

Phase 3

339

Bois-Guillaume, Dijon, Lyon, Montivilliers, Nantes, Paris, Poitiers, Toulouse

2024-06-29

Recruiting

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

NCT06324357Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma

DrugsZongertinib·Zanidatamab·Trastuzumab emtansine·MFOLFOX6

Boehringer Ingelheim

Phase 1/2

768

Bordeaux, Caen, Lyon, Marseille, Paris, Rennes, Saint-Herblain, Strasbourg

2024-06-28

Recruiting

A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)

NCT06263231Sarcoma,Soft Tissue

DrugsINT230-6·Trabectedin·Pazopanib·Eribulin

Intensity Therapeutics, Inc.

Phase 3

333

Lyon

2024-06-28

Active, closed

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06468228Hidradenitis Suppurativa

DrugLutikizumab

AbbVie

Phase 3

1,400

Lyon, St-Priest-en-Jarez, Martigues, Rouen, Paris, Reims

2024-06-27

Recruiting

Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer

NCT06712472Endometrial Cancer, p53abn

DrugOlaparib

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3

554

Albi, Angers, Besançon, Carcassonne, Dijon, Grenoble, Limoges, Lyon

2024-06-26

Recruiting

First Observatory of Precocious Puberty.

NCT06263868Puberty, Precocious

Hospices Civils de Lyon

Observational

3,360

Écully, Lyon, Rennes, Chambray-lès-Tours, Essey-lès-Nancy, Levallois-Perret, Fondettes, Lormont

2024-06-26

Active, closed

Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma

NCT06353022Multiple Myeloma

DrugsTalquetamab·Teclistamab·Bortezomib·Daratumumab

Nantes University Hospital

Phase 2

103

Bayonne, Caen, Dijon, La Roche-sur-Yon, Lille, Limoges, Lyon, Marseille

2024-06-26

Active, closed

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

NCT06496178Head and Neck Squamous Cell Carcinoma

DrugPetosemtamab

Merus B.V.

Phase 3

621

Bordeaux, Brest, Le Mans, Lille, Lyon, Marseille, Montpellier, Nice

2024-06-25

Recruiting

REmote COnditioning in Out-of-Hospital Cardiac Arrest

NCT06306625Out-Of-Hospital Cardiac Arrest

Hospices Civils de Lyon

Not applicable

220

Bron, Clermont-Ferrand, Dijon, La Tronche, Lyon, Marseille, Montpellier, Nîmes

2024-06-21

Recruiting

Developing a Complex ex Vivo Endometrial Tissue Model to Improve Endometriosis Care

NCT06331676Endometriosis

Hospices Civils de Lyon

Not applicable

Bron, Lyon

2024-06-21

Recruiting

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

NCT06455449Polymyositis, Dermatomyositis

AstraZeneca

Phase 3

240

Angers, Brest, Le Mans, Lille, Lyon, Paris, Reims, Rouen

2024-06-20

Recruiting

Evaluation of a Dimensional Adaptation of Good Psychiatric Management (GPM-extended) for the Treatment of Borderline Personality Disorder

NCT06913738Borderline Personality Disorder, Narcissism, Obsessive Compulsive Personality Disorder, Personality Disorder

AddiPsy

Not applicable

154

Bayonne, Lyon

2024-06-19

Active, closed

A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

NCT06388733Glioblastoma, GBM, Brain Neoplasms, Adult, Malignant, Brain Tumor

DrugsTemodar·Niraparib·Temozolomide

Ivy Brain Tumor Center

Phase 3

450

Nice, Marseille, Montpellier, Rennes, Saint-Herblain, Paris, Bron, Lyon

2024-06-19

Active, closed

Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia

NCT06455059Hypochondroplasia

DrugVosoritide

BioMarin Pharmaceutical

Phase 3

Lyon, Marseille, Paris, Toulouse

2024-06-17

Recruiting

National Registry of Surgical Treatment and Percutaneous Cryoablation of Parietal Endometriosis

NCT06356831Endometriosis, Cryotherapy Effect, Surgical, Radiology

Centre Hospitalier Intercommunal Creteil

Observational

300

Bordeau, Bordeaux, Clermont-Ferrand, Créteil, Lyon, Marseille, Montpellier, Nîmes

2024-06-15

Recruiting

Compliance and Tolerance to Oral AntiBiotherapy in Osteoarticular Infections (OTABIO)

NCT05202964Drug-Related Side Effects and Adverse Reactions, Treatment Adherence and Compliance

Hospices Civils de Lyon

Observational

Lyon

2024-06-13

Recruiting

Impact of a Multidisciplinary Assessment in Day Hospitalization Versus Standard Care on the Deployment of Supportive Oncology Care Recommended by the Personalized Post-cancer Plan in Patients at the End of Initial Treatment for Gynecological Ovarian and Endometrial Cancer Endometrial Cancer

NCT06553612Gynecologic Cancer, Remission

Centre Francois Baclesse

Not applicable

268

Besançon, Caen, Clermont-Ferrand, Lyon, Paris, Plérin, Saint-Cloud, Saint-Etienne

2024-06-07

Active, closed

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT06082167Head and Neck Squamous Cell Carcinoma

DrugsZanzalintinib·Keytruda·Pembrolizumab

Exelixis

Phase 2/3

600

Marseille, Bordeaux, Rennes, Saint Priest En Jarez, Lyon, Le Mans, Villejuif, Dijon

2024-06-07

Active, closed

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT06425991Multiple Myeloma

DrugTeclistamab

Janssen Research & Development, LLC

Phase 1

108

Lille, Lyon, Nantes, Pessac

2024-06-07

Recruiting

MAQ-001 in Patients With Advanced Solid Tumors

NCT06514651Advanced Solid Tumor

DrugsYervoy·Ipilimumab

MabQuest SA

Phase 1

Lyon, Paris, Rennes, Toulouse

2024-06-06

Recruiting

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

NCT06056297Neutropenia

X4 Pharmaceuticals

Phase 3

176

Lyon, Paris, Rennes, Toulouse

2024-06-06

Active, closed

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer

DrugsTarlatamab·Durvalumab

Amgen

Phase 3

563

Bordeaux, Brest, Créteil, Le Mans, Lyon, Marseille, Montpellier, Paris

2024-06-05

Recruiting

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

NCT06479135Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis

DrugsNavtemadlin·Jakavi·Ruxolitinib

Kartos Therapeutics, Inc.

Phase 3

600

Paris, Amiens, Angers, Lille, Lyon, Nantes, Nice, Nîmes

2024-06-03

Recruiting

Superiority Trial Evaluating Digitalized Information Media for Patients With Advanced Sarcomas Receiving Systemic Treatment.

NCT06211257Sarcoma Metastatic, Locally Advanced Soft Tissue Sarcoma

Centre Oscar Lambret

Not applicable

377

Lyon, Besançon, Rennes, Strasbourg, Lille, Poitiers, Toulouse, Saint-Herblain

2024-05-29

Active, closed

Use of a Treated, Devitalized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of STT Osteoarthritis

NCT06038331Osteoarthritis Hand

TBF Genie Tissulaire

Phase 2

Besançon, Lyon, Nantes, Strasbourg

2024-05-28

Recruiting

ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients

NCT06195709Breast Carcinoma

Institut Curie

Phase 3

300

Bayonne, Bordeaux, Caen, Dijon, Lille, Limoges, Lyon, Marseille

2024-05-27

Recruiting

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis

DrugPegozafermin

Hoffmann-La Roche

Phase 3

1,800

Amiens, Clichy, Dijon, Limoges, Lyon, Montpellier, Nice, Paris

2024-05-24

Recruiting

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

NCT06203210Small Cell Lung Cancer

DrugsAmrubicin·Ifinatamab Deruxtecan·Lurbinectedin·Topotecan

Daiichi Sankyo

Phase 3

540

Avignon, Bordeaux, Créteil, Lille, Limoges, Lyon, Marseille, Montpellier

2024-05-21

Recruiting

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

NCT06400472Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung

DrugsSofe-M·Itraconazole·Bevacizumab·Carboplatin

Eli Lilly and Company

Phase 1

575

Lyon, Saint-Herblain, Toulouse

2024-05-20

Recruiting

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection

Vedanta Biosciences, Inc.

Phase 3

852

Les Paris, Dijon, Paris, Bordeaux Cedex, Garches, Nantes, Lyon, Tours

2024-05-20

Recruiting

Prognostic Value of High-resolution Electrical Source Imaging on the Success of Pediatric Focal Epilepsy Surgery

NCT06271785Epilepsy in Children

University Hospital, Angers

Not applicable

120

Angers, Lille, Lyon, Marseille, Nancy, Paris, Rennes

2024-05-15

Active, closed

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

NCT06295731Head and Neck Squamous Cell Carcinoma (HNSCC)

DrugsKeytruda·Pembrolizumab

Inhibrx Biosciences, Inc

Phase 2/3

410

Annecy, Metz, Clermont-Ferrand, Lille, Lyon

2024-05-14

Recruiting

Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients

NCT06306014Clostridioides Difficile Infection, Recurrent Infection

DrugEXL01

Hospices Civils de Lyon

Phase 1/2

Annecy, Clermont-Ferrand, Grenoble, Lille, Lyon, Marseille, Paris, Saint-Etienne

2024-05-07

Recruiting

Multi-parametric MRI Evaluation of Renal Graft Performance After Living Donor Donation.

NCT06047106Renal Insufficiency, Chronic

DrugBlood samples

Hospices Civils de Lyon

Not applicable

Lyon

2024-05-07

Recruiting

DECIdE, Shared DECIsion in hEalth : the Real-life Impact Study

NCT06052917Decision Making, Shared

University Hospital, Clermont-Ferrand

Not applicable

288

Clermont-Ferrand, Grenoble, Lyon, Saint-Etienne

2024-05-05

Active, closed

Vitiligo Treatment by Targeting TYK2 Mediated Responses

NCT06327321Vitiligo, Generalized

DrugDeucravacitinib

Centre Hospitalier Universitaire de Nice

Phase 2

128

Nice, Paris, Bordeaux, Lille, Lyon

2024-05-05

Active, closed

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

NCT06356311Gastroesophageal Cancer

DrugsTrifluridine/Tipiracil·Sacituzumab tirumotecan·Irinotecan·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

473

Bordeaux, Lyon, Caen, Toulouse, Lille, Rennes, Poitiers, Paris

2024-05-03

Recruiting

Impact of Rifampicin in Treatment Outcome of Cutibacterium Acnes Prosthetic Joint Infections

NCT05902221Infections Joint Prosthetic

DrugsRifampicin·Moxifloxacin·Amoxicillin

Centre Hospitalier Universitaire de Nice

Phase 3

235

Annecy, Bordeaux, Boulogne, Lyon, Marseille, Montpellier, Nantes, Nice

2024-05-02

By invitation

Vascular Access for Minimally-invasive Leadless Pacemaker Implantation Through the Right Jugular routE

NCT06455566Leadless Pacemaker, Same-day Discharge

University Hospital, Caen

Observational

200

Angers, Caen, Grenoble, Lille, Lyon, Metz, Montpellier, Nîmes

2024-05-01

Active, closed

Renal Futility Following Simultaneous Liver-Kidney Transplantation

NCT06712537Simultaneous Liver-kidney Transplantation

Hospices Civils de Lyon

Observational

452

Lyon

2024-05-01

Active, closed

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

NCT06346067Advanced or Metastatic NRAS-mutant Melanoma

DrugsNaporafenib·Temodar·Dacarbazine·Trametinib

Erasca, Inc.

Phase 3

Bordeaux, Dijon, Le Mans, Lille, Lyon, Marseille, Paris, Villejuif

2024-04-29

Recruiting

Study Evaluating the Efficacy of the myDIET Software Tool in the Nutritional Management of Patients With Localized and Resectable Gastric or Esogastric Junction Cancer.

NCT06385691Gastric Cancer, Oesogastric Junction Cancer

Centre Leon Berard

Phase 2

Lyon

2024-04-26

Recruiting

Assessment of Collagen Membrane Interest in Distal Cuff Lesions Repair

NCT06269965Cuff Rotator Syndrome

GCS Ramsay Santé pour l'Enseignement et la Recherche

Not applicable

204

Lyon

2024-04-23

Recruiting

Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin Carboxy-terminal Hydrolase L1 (UCH-L1) to Exclude Lesions Linked to Significant Traumatic Brain Injuries

NCT05885529Traumatic Brain Injury

Centre Hospitalier Princesse Grace

Observational

1,500

Angers, Clermont-Ferrand, Dijon, Grenoble, Lyon, Montpellier, Nantes, Nice

2024-04-19

Recruiting

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

NCT06319820Non-Muscle Invasive Bladder Neoplasms

DrugGemcitabine

Janssen Research & Development, LLC

Phase 3

641

Lille, Limoges, Lyon, Marseille, Paris, Quint-Fonsegrives, Rennes, Toulouse

2024-04-18

Recruiting

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

NCT06312176Breast Neoplasms

DrugsLiposomal doxorubicin·Abraxane·Xeloda·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

1,200

Lyon, Caen, Montpellier, Nantes, Poitiers, Paris

2024-04-14

Recruiting

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

NCT06330064Recurrent or Metastatic Solid Tumors

DrugIfinatamab Deruxtecan

Daiichi Sankyo

Phase 1/2

680

Dijon, Bordeaux, Montpellier, Rennes, Saint-Herblain, Paris, Lyon, Villejuif

2024-04-10

Recruiting

Transpulmonary Pressure - Guided Mechanical Ventilation in Morbidly Obese ARDS Patients: a Feasibility Study.

NCT06119516ARDS, Human, Obesity, Morbid

Assistance Publique - Hôpitaux de Paris

Not applicable

Angers, Le Kremlin-Bicêtre, Lyon, Paris, Poitiers

2024-04-04

Active, closed

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

NCT06329401Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease

DrugPirfenidone

Avalyn Pharma Inc.

Phase 2

398

Rennes, Tours, Metz, Lyon, Montpellier, Angers, Le Kremlin-Bicêtre, Paris

2024-04-03

Active, closed

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

NCT06305247Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer

Ipsen

Phase 1/2

Lyon, Paris, Saint-Herblain, Villejuif

2024-04-03

Recruiting

Spatial Hearing Rehabilitation in Noise for Bilateral Cochlear Implant Children

NCT06040892Cochlear Implantation

Hospices Civils de Lyon

Not applicable

Lyon

2024-03-27

Recruiting

A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)

NCT06163430Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia

DrugHS-10382

Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1/2

330

Lyon, Bordeaux, Marseille, Nantes, Paris, Pierre-Bénite

2024-03-26

Recruiting

Evaluation Contact X-ray Brachytherapy for Rectal Preservation in Intermediate Substage Rectal Adenocarcinoma

NCT06402864Adult With Intermediate Low or Mid Rectal Adenocarcinoma

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3

212

Avignon, Lyon, Marseille, Mâcon, Nice, Saint-Etienne, Saint-Herblain, Villejuif

2024-03-26

Recruiting

Bougie Versus Endotracheal Tube Alone on First-attempt Intubation Success in Prehospital Emergency Intubation (BETA Trial)

NCT06307392Acute Respiratory Failure Requiring Intubation

Nantes University Hospital

Not applicable

710

Nantes, Besançon, Bordeaux, Clermont-Ferrand, La Roche-sur-Yon, Lorient, Lyon, Nancy

2024-03-26

Recruiting

Evaluation of the Performance of the IDBIORIV Method in Pathogen Identification and Antibiotic Susceptibility Testing in Patients With Sepsis

NCT06219135Sepsis

Hospices Civils de Lyon

Observational

1,372

Bron, Lyon, Pierre-Bénite, Villeurbanne

2024-03-21

Recruiting

Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome

NCT06186648Richter Syndrome

DrugsGlofitamab·Obinutuzumab

French Innovative Leukemia Organisation

Phase 2

Amiens, Angers, Bayonne, Clermont-Ferrand, Grenoble, Lille, Limoges, Lyon

2024-03-21

Active, closed

REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study

NCT06041386Asthma

DrugMepolizumab

GlaxoSmithKline

Phase 4

336

Brest, Cannes, Lille, Lyon, Strasbourg, Toulouse

2024-03-20

Recruiting

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

NCT06072781Low Grade Serous Ovarian Cancer

DrugsAvutometinib·Defactinib·Pegylated liposomal doxorubicin·Anastrozole

Verastem, Inc.

Phase 3

270

Besançon, Dijon, Lille, Lyon, Paris

2024-03-18

Active, closed

Management of Bone Metastases

NCT06713941Cancer, Bone Metastases

Hospices Civils de Lyon

Observational

900

Brest, Lyon

2024-03-15

Recruiting

Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study

NCT05904119First Progression of Glioblastoma

DrugLomustine

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3

411

Amiens, Clermont-Ferrand, Lille, Lyon, Montpellier, Nice, Paris, Saint-Herblain

2024-03-15

Active, closed

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

NCT06132893Focal Epilepsy

DrugOpakalim

Biohaven Therapeutics Ltd.

Phase 2/3

390

Strasbourg, Dijon, Toulouse, Montpellier, Tours, Nancy, Lille, Lyon

2024-03-14

Recruiting

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

DrugPegozafermin

Hoffmann-La Roche

Phase 3

1,350

Amiens, Angers, Bordeaux, Clichy, Lille, Limoges, Lyon, Montpellier

2024-03-13

Recruiting

Fine Needle Aspiration (FNA) Evaluation of the Intrahepatic HBV Reservoir and Its Immunological Characteristics in Chronically HBV-infected Patients

NCT06047093Chronic Hepatitis b

Hospices Civils de Lyon

Not applicable

100

Lyon

2024-03-08

Active, closed

A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

NCT06318273Metastatic Castration-Resistant Prostate Cancer

AbbVie

Phase 1

152

Lille, Lyon, Villejuif

2024-03-08

Active, closed

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

NCT06292013Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)

DrugLepodisiran

Eli Lilly and Company

Phase 3

17,300

Bobigny, Bron, Chambray-lès-Tours, Compiègne, Dijon, Le Coudray, Lille, Lyon

2024-03-05

Active, closed

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

NCT06238479Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm

Eli Lilly and Company

Phase 1

490

Lille, Lyon, Marseille, Strasbourg, Villejuif

2024-03-05

Recruiting

Analgesic Effectiveness of Capsaicin 8% Cutaneous Patch in Children

NCT05997979Neuropathic Pain, Chronic Pain

DrugCapsaicin

University Hospital, Brest

Phase 3

Amiens, Angers, Bordeaux, Brest, Lyon, Marseille, Montpellier, Tours

2024-03-05

Active, closed

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

NCT06346392Gastric Cancer, Gastroesophageal Junction Cancer

DrugsSonesitatug Vedotin·Ramucirumab·Trifluridine/Tipiracil·Apatinib

AstraZeneca

Phase 3

594

Besançon, Brest, Lille, Lyon, Nantes

2024-03-04

Recruiting

Cryoablation Versus Medical Therapy in Desmoid Tumors Progressing After Watchful Waiting

NCT06081400Desmoid Tumor

University Hospital, Strasbourg, France

Not applicable

150

Besançon, Bordeaux, Caen, Dijon, Lyon, Marseille, Nantes, Nice

2024-03-04

Not yet open

Maxillofacial Rehabilitation Using Motor Imagery vs Sham After Orthognathic Surgery

NCT06263374Maxillofacial Abnormalities

Hospices Civils de Lyon

Not applicable

100

Lyon, Saint-Genis-Laval

2024-03-01

Recruiting

Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)

NCT06165341Alpha1-Antitrypsin Deficiency

DrugFazirsiran

Takeda

Phase 3

Lyon, Rennes, Val-de-Marne

2024-03-01

Recruiting

DEprescribing: Perceptions of PAtients Living With Advanced Cancer

NCT06193083Deprescribing, Palliative Care, Oncology

Nantes University Hospital

Observational

325

La Roche-sur-Yon, Lyon, Nantes, Paris, Saint-Herblain, Saint-Nazaire, Tours

2024-02-28

Recruiting

Identification of Y Chromosome From Free Circulating DNA in Patients With Turner Syndrome

NCT06202846Turner Syndrome

University Hospital, Strasbourg, France

Not applicable

Lyon, Strasbourg

2024-02-28

Recruiting

Impact of Implementing the Modified A-DIVA Scale on Successful Access to a Venous Line on the First Attempt

NCT06062199Chronic Disease

Centre Jean Perrin

Not applicable

200

Clermont-Ferrand, Lyon

2024-02-27

Recruiting

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT06161025Solid Cancer

DrugsR-DXd·Topotecan·Paclitaxel

Daiichi Sankyo

Phase 2/3

860

Bordeaux, Caen, Clermont-Ferrand, Dijon, Lyon, Marseille, Montpellier, Nantes

2024-02-27

Recruiting

Unexpected Positive Cultures in Rotator Cuff Revision Surgery

NCT06257979Rotator Cuff Repair

Elsan

Not applicable

132

Beaumont, Caen, Essey-lès-Nancy, Lyon, Muret, Nice, Saint-Herblain, Strasbourg

2024-02-27

Recruiting

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer

DrugPatritumab deruxtecan

Daiichi Sankyo

Phase 2

740

Bordeaux, Dijon, Lille, Lyon, Marseille, Nantes, Toulouse, Vandœuvre-lès-Nancy

2024-02-26

Recruiting

Long-term Cognitive and Functional Impact of Proton-therapy or Modern Fractionated Radiotherapy in Cavernous Sinus Meningioma: An Open-label Randomized 1:1 Phase III Study

NCT05895344Cavernous Sinus Meningioma, Proton-therapy, Photon Radiotherapy, Cognitive Impairment

Centre Francois Baclesse

Not applicable

160

Caen, Clamart, Grenoble, Le Havre, Lyon, Nice, Paris, Saint-Cloud

2024-02-26

Active, closed

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

NCT06239467Advanced Cancer, Breast Cancer, Advanced Solid Tumors, PI3K Gene Mutation

DrugsAtirmociclib·Tucatinib·Ribociclib·Fulvestrant

OnKure, Inc.

Phase 1

200

Dijon, Lille, Lyon, Nice, Pierre-Bénite, Villejuif

2024-02-26

Recruiting

SNV1521 in Participants With Advanced Solid Tumors

NCT06220864Advanced Solid Tumor

DrugsDB-1310·Abiraterone·Darolutamide

ParVation Therapeutics, Inc.

Phase 1

400

Bordeaux, Lyon, Villejuif

2024-02-23

Recruiting

Efficacy of 7 Days Versus 14 Days of Antibiotic Therapy for Acute Pyelonephritis in Kidney Transplant Recipients, a Multicentre Randomized Non-inferiority Trial.

NCT05597540Pyelonephritis Acute, Kidney Transplant Infection

Assistance Publique - Hôpitaux de Paris

Phase 3

470

Bordeaux, Boulogne-Billancourt, Créteil, Lyon, Nantes, Paris, Toulouse

2024-02-22

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy

NCT05979311HIV, HIV Infections

DrugsBictegravir·Dolutegravir·Emtricitabine·Lamivudine

ViiV Healthcare

Phase 3

463

Bordeaux, Lyon, Montpellier, Nice, Nîmes, Paris

2024-02-21

Recruiting

Evaluation of the Quality of Life and Tolerance of Patients Treated With Vectorized Internal Radiotherapy (RIV) for a Neuro Endocrine Tumor (NET) in the Auvergne-Rhône-Alpes Region.

NCT06043193Metastatic Neuroendocrine Tumour

Hospices Civils de Lyon

Observational

100

Saint-Priest-en-Jarez, Chambéry, Clermont-Ferrand, Lyon

2024-02-20

Active, closed

Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.

NCT05930275Crohn's Disease

AbbVie

Observational

1,200

Nice, Clermont, Lyon, Marseille, Dijon, Pessac, Toulouse, Montpellier

2024-02-19

Recruiting

EGEA4 THE 30 YEAR FOLLOW UP OF THE EGEA STUDY

NCT06334705Healthy Volunteer EGEA4 Cohort

Institut National de la Santé Et de la Recherche Médicale, France

Not applicable

1,000

Grenoble, Lyon, Marseille, Montpellier, Paris

2024-02-15

Recruiting

Treatment of Upper Limb Chronic Neuropathic Pain by Electrical Stimulation of the Brachial Plexus Nerve Roots

NCT05817786Neuralgia

Centre Hospitalier Universitaire de Nice

Not applicable

Lyon, Nice, Poitiers

2024-02-09

Active, closed

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

NCT06151574Lung Cancer, Non-squamous, Non-small Cell

DrugsZongertinib·Pemetrexed·Keytruda·Cisplatin

Boehringer Ingelheim

Phase 3

428

Bron, Lyon, Marseille, Paris, Rennes, Strasbourg, Toulouse, Villejuif

2024-02-09

Recruiting

Evaluation of Integrated Versus Parallel Connection for Renal Replacement Therapy in ECMO Patients

NCT06038162Venoarterial Extracorporeal Membrane Oxygenation, Renal Replacement Therapy, Acute Kidney Injury

Hospices Civils de Lyon

Not applicable

158

Bordeaux, Clermont-Ferrand, Dijon, Grenoble, Lille, Lyon, Montpellier, Paris

2024-02-07

Recruiting

Assessment of the Quality and Sexual Health Needs of Patients with Advanced-stage Cancer

NCT06229158Advanced Cancer, Sexual Satisfaction

Hospices Civils de Lyon

Observational

120

Lyon

2024-02-05

Recruiting

TOngue/Palate Interactions Study

NCT03966131Toothless

Hospices Civils de Lyon

Not applicable

Lyon

2024-02-02

Recruiting

ESCAPE : Evaluation of Spinal Conservation by Endoscopic Procedures to Avoid Fusion

NCT06950853Spinal Stenosis, Spondylolisthesis

University Hospital, Bordeaux

Observational

375

Bordeaux, Bruges, Lille, Lyon, Marseille, Narbonne, Osny, Pessac

2024-02-01

Active, closed

A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06212999Hidradenitis Suppurativa (HS)

DrugPovorcitinib

Incyte Corporation

Phase 3

617

Bordeaux, Brest, Dijon, Le Mans, Lyon, Marseille, Nantes, Nice

2024-01-30

Not yet open

Role of BMP Pathway in MDS Progression

NCT06175923Myelodysplastic Syndromes, Acute Myelogenous Leukemia

Hospices Civils de Lyon

Observational

Lyon

2024-01-27

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

NCT06004245Advanced Solid Tumors, Colorectal Cancer

DrugsVVD-133214·Avastin·Keytruda·Bevacizumab

Vividion Therapeutics, Inc.

Phase 1

280

Lyon, Montpellier, Paris, Toulouse, Villejuif

2024-01-25

Active, closed

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

NCT06208150Multiple Myeloma

DrugsElotuzumab·Talquetamab·Velcade·Teclistamab

Janssen Research & Development, LLC

Phase 3

838

Lille, Limoges, Lyon, Marseille, Nantes, Paris, Pessac, Strasbourg

2024-01-22

Recruiting

DEWI: Watch-and-Wait With Dostarlimab in Localized dMMR/MSI-H Gastric/GEJ Adenocarcinoma Phase II Study

NCT06059495Adenocarcinoma - GEJ, Gastric Adenocarcinoma

DrugDostarlimab

GERCOR - Multidisciplinary Oncology Cooperative Group

Phase 2

Besançon, Bordeaux, Brest, Créteil, Lille, Lyon, Marseille, Montpellier

2024-01-22

Recruiting

Impact of a Protocol for Announcing Decision of Withholding and Withdrawing Life-sustaining Treatments on the Stress of the Relatives in the Emergency Departments

NCT06071078End of Life

Hospices Civils de Lyon

Not applicable

538

Angers, Bourg-en-Bresse, Clermont-Ferrand, Grenoble, Lyon, Toulouse, Villefranche-sur-Saône

2024-01-19

Recruiting

Contribution of Fast-ripples to the Improvement of the Neurosurgical Management of Drug-refractory Epilepsy

NCT06105645Epilepsy

University Hospital, Toulouse

Not applicable

440

Amiens, Bordeaux, La Tronche, Le Kremlin-Bicêtre, Lille, Lyon, Nancy, Paris

2024-01-19

Recruiting

PASCA-MM Study. Impact of the PASCA (PArcours de Santé au Cours du CAncer) Program on Complications Associated With Multiple Myeloma and/or Its Treatments in the Context of a First Hematopoietic Stem Cell Autograft, in Adults Aged 18 to 70.

NCT05947136Multiple Myeloma, Complication

Centre Leon Berard

Not applicable

204

Épagny, Grenoble, Lyon, Montpellier, Saint-Etienne, Villefranche-sur-Saône

2024-01-19

Recruiting

Prediction of Residual Disease by Circulating DNA Detection After Potentiated Radiotherapy for Locally Advanced Head and Neck Cancer

NCT05710679Locally Advanced Head and Neck Carcinoma

DrugBlood sample

Centre Jean Perrin

Not applicable

Clermont-Ferrand, Aurillac, Lyon, Saint-Etienne

2024-01-17

Recruiting

ALL Reconstruction Versus Modified Lemaire's LET in Combination With ACL Reconstruction With a Minimum Follow up of 2 Years

NCT06147427Anterior Cruciate Ligament Injuries

Hospices Civils de Lyon

Not applicable

248

Lyon

2024-01-16

By invitation

Evaluation of the Efficacy of the ALLYANE Procedure in the Treatment of Central Motor Inhibition

NCT06774157Arthrogenic Muscle Inhibition, Arthrogenic Muscle Inhibitions

Allyane

Not applicable

120

Lyon

2024-01-15

Recruiting

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

NCT06064877Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma

DrugsErbitux·Cetuximab

AVEO Pharmaceuticals, Inc.

Phase 3

410

Brest, Chambray-lès-Tours, Lyon, Marseille, Paris, Plérin, Villejuif

2024-01-11

Recruiting

ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases

NCT05787197Metastatic Colorectal Cancer, Circulating Tumor DNA

GERCOR - Multidisciplinary Oncology Cooperative Group

Observational

232

Besançon, Bordeaux, Lille, Lyon, Paris, Pessac, Poitiers, Rouen

2024-01-09

Recruiting

MRI Guided Radiotherapy and Radiobiological Data: the ISRAR Database (Irm Sequences for Radiobiological Adaptative Radiotherapy)

NCT06041555Prostate Cancer, Glioblastoma, Head and Neck Cancer, Kidney Cancer

Hospices Civils de Lyon

Observational

600

Lyon

2024-01-08

Recruiting

Impact of Forced Diuresis on the Residual Fragment Rate After Flexible Ureteroscopy for Destruction of Kidney Stones With Laser

NCT05916963Kidney Stone

DrugFurosemide

University Hospital, Tours

Phase 3

374

Angers, Lyon, Nice, Nîmes, Rennes, Rouen, Toulouse, Tours

2024-01-04

Recruiting

Assessment of the Type I IFN Response in the Nasal Cavity During Respiratory Viral Infections in a Geriatric Department

NCT07601412Respiratory Viral Infection

Hospices Civils de Lyon

Observational

1,140

Lyon

2024-01-04

Recruiting

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

NCT06179160Solid Tumors

DrugsGEMNabP·INCA33890·INCB161734·Retifanlimab

Incyte Corporation

Phase 1

710

Lyon, Toulouse, Villejuif

2024-01-04

Recruiting

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

NCT06090539Relapsed/Refractory Non-Hodgkin Lymphoma

DrugsGolcadomide·Mosunetuzumab·Epcoritamab·Truxima

Bristol-Myers Squibb

Phase 1/2

460

Bordeaux, Lyon, Lille, Villejuif, Créteil, Montpellier, Paris, Toulouse

2023-12-29

Recruiting

BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT

NCT06059638Hypertension, Hypertension, Systolic, Hypertension, Essential

Orchestra BioMed, Inc

Not applicable

316

Grenoble, Lyon, Nantes, Paris, Tours

2023-12-27

Active, closed

Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

NCT05948475Cholangiocarcinoma

DrugTinengotinib

TransThera Sciences (Nanjing), Inc.

Phase 3

200

Avignon, Besançon, Clichy, Levallois-Perret, Lyon, Montpellier, Paris, Villejuif

2023-12-20

Recruiting

Global Trial in APG2575 for Patients With CLL/SLL

NCT06104566CLL/SLL

DrugLisaftoclax

Ascentage Pharma Group Inc.

Phase 3

400

Clermont-Ferrand, Le Mans, Lyon, Nantes, Nîmes, Orléans, Poitiers, Pontoise

2023-12-20

Recruiting

Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC

NCT05718323SCLC,Extensive Stage, SLFN11-positive

DrugNiraparib

ETOP IBCSG Partners Foundation

Phase 2

Angers, Avignon, Caen, Lyon

2023-12-20

Recruiting

Clinical Improvement Obtained by Endoscopic Ilio-Psoas Tenotomy (Lesser Trochanter Versus Acetabular Notch)

NCT05950022Tendinopathy

GCS Ramsay Santé pour l'Enseignement et la Recherche

Not applicable

108

Lyon

2023-12-19

Active, closed

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

NCT06118411Vitiligo

DrugUpadacitinib

AbbVie

Phase 3

614

Nice, Bordeaux, Toulouse, Créteil, Lyon

2023-12-19

Recruiting

Preoperative Radiotherapy And ASTX660 in Rectum Cancer

NCT05912075Locally-advanced Rectal Cancer

DrugsTolinapant·FOLFOX4·MFOLFIRINOX·Folfox

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1

Lyon, Villejuif

2023-12-19

Recruiting

Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease

NCT05800275Leptomeningeal Metastasis, Leptomeningeal Disease, HER2-positive Metastatic Breast Cancer

DrugsTucatinib·Trastuzumab·Capecitabine

UNICANCER

Phase 2

Bordeaux, Caen, Clermont-Ferrand, Dijon, Lyon, Montpellier, Nice, Reims

2023-12-18

Recruiting

Early Deresuscitation Strategy Driven by Tissue Perfusion in Renal Replacement Therapy in Patients With Acute Renal Failure

NCT05817539Acute Kidney Injury, Fluid Overload

Hospices Civils de Lyon

Not applicable

250

Ajaccio, Amiens, Bron, Caen, Dijon, Le Plessis-Robinson, Lille, Lyon

2023-12-15

Recruiting

A Study of JNJ-87890387 for Advanced Solid Tumors

NCT06178614Neoplasms, Advanced Solid Tumors

Janssen Research & Development, LLC

Phase 1

200

Lyon, Villejuif

2023-12-14

Recruiting

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma

DrugVolrustomig

AstraZeneca

Phase 3

1,145

Avignon, Bordeaux, Le Mans, Lyon, Nice, Saint-Herblain, Toulouse, Villejuif

2023-12-14

Recruiting

Response Profiles to High-concentration Capsaicin Desensitization in Patients with Peripheral Neuropathic Pain with or Without Allodynia: a Regional Multicenter Prospective Cohort

NCT05817591Peripheral Neuropathic Pain

Centre Hospitalier Annecy Genevois

Observational

400

Annecy, Bron, Chambéry, Clermont-Ferrand, Grenoble, Lyon, Saint-Etienne, Villeurbanne

2023-12-14

Active, closed

A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib

NCT05734105GIST

DrugsRipretinib·Sunitinib

Deciphera Pharmaceuticals, LLC

Phase 3

Dijon, Rennes, Bordeaux, Lyon, Villejuif

2023-12-13

Recruiting

Azathioprine in MOGAD

NCT05349006Central Nervous System Inflammation, MOG-IgG Associated Disease

DrugAzathioprine

Hospices Civils de Lyon

Phase 3

126

Bordeaux, Lille, Lyon, Marseille, Montpellier, Nancy, Nice, Nîmes

2023-12-12

Recruiting

Predict Tooth Wear

NCT06681844Prediction of Tooth Wear

Hospices Civils de Lyon

Observational

1,000

Lyon

2023-12-12

Active, closed

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

NCT06065748Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

DrugsGiredestrant·Ribociclib·Abemaciclib·Palbociclib

Hoffmann-La Roche

Phase 3

1,050

Angers, Avignon, Besançon, Caen, Clermont-Ferrand, La Rochelle, Lille, Lyon

2023-12-11

Recruiting

Study for Characterisation of Predictive Parameters of Clonal Evolution in Subjects With GATA2 Germline Mutation

NCT05983991GATA2 Gene Mutation

Institut Claudius Regaud

Not applicable

150

Angers, Bordeaux, Caen, Clermont-Ferrand, Dijon, Grenoble, Lille, Lyon

2023-12-07

Active, closed

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

NCT06007690Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma

DrugBel-sar

Aura Biosciences

Phase 3

108

Nice, Lyon

2023-12-06

Recruiting

LUNG INFECTION in ICU (LUNG-I3)

NCT06073834VAP - Ventilator Associated Pneumonia

BioMérieux

Observational

Lyon

2023-12-05

Recruiting

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

NCT06215716NASH With Fibrosis, MASH With Fibrosis

DrugEfruxifermin

Akero Therapeutics, Inc

Phase 3

1,650

Nice, Lyon, Strasbourg, Limoges, Clichy, Vandœuvre-lès-Nancy, Angers, Toulouse

2023-12-01

Recruiting

The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)

NCT06408441Epithelioid Hemangioendothelioma, Sarcoma,Soft Tissue

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Observational

100

Lyon, Lille

2023-12-01

Recruiting

Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer

NCT05872204Low Grade Serous Ovarian Carcinoma, Adult Type Granulosa Cell Tumor

DrugsAbemaciclib·Letrozole

Universitaire Ziekenhuizen KU Leuven

Phase 2

100

Strasbourg, Bordeaux, Toulouse, Saint-Herblain, Lyon, Paris

2023-11-30

Recruiting

A Study to Evaluate Pre-operative HYPOfractionated Radiation Therapy in Aged (≥ 70 Years Old) or "Fragile" (≥ 65 Years) Patients With Limb or Trunk Soft Tissue SARComa.

NCT06022159Soft Tissue Sarcoma

Institut Claudius Regaud

Phase 2

Bordeaux, Lille, Limoges, Lyon, Montpellier, Paris, Poitiers, Saint-Herblain

2023-11-28

Recruiting

A Multicenter Multinational Observational Study of Children With Hypochondroplasia

NCT06212947Hypochondroplasia

BioMarin Pharmaceutical

Observational

400

Lyon, Marseille, Paris, Toulouse

2023-11-27

Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

NCT06103864Breast Cancer

DrugsDato-DXd·Durvalumab·Nab-paclitaxel·Gemcitabine

AstraZeneca

Phase 3

625

Lille, Lyon, Montpellier, Paris, Saint-Herblain, Toulouse, Vandœuvre-lès-Nancy, Villejuif

2023-11-23

Recruiting

Development of Targeted RNA-Seq for Amyotrophic Lateral Sclerosis Diagnosis

NCT06083584Amyotrophic Lateral Sclerosis

Centre Hospitalier Universitaire de Nīmes

Observational

192

Bordeaux, Clermont-Ferrand, Lyon, Marseille, Montpellier, Nîmes, Toulouse

2023-11-22

Active, closed

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

NCT06120491Metastatic Castration-Sensitive Prostate Cancer

DrugsSaruparib·Zytiga·Xtandi·Abiraterone acetate

AstraZeneca

Phase 3

1,898

Angers, Bayonne, Bordeaux, Caen, Clermont-Ferrand, Créteil, Lyon, Montpellier

2023-11-21

Active, closed

The PEERLESS II Study

NCT06055920Pulmonary Embolism

Inari Medical

Not applicable

1,200

Lille, Lyon, Marseille

2023-11-17

Recruiting

Impact of Bacterial Expression and Immune Response in the Severity of Pertussis

NCT05897879Bordetella Pertussis, Whooping Cough

DrugsNasopharyngeal swab·Blood samples

Institut Pasteur

Not applicable

210

Bordeaux, Colombes, Créteil, Lille, Lyon, Marseille, Nantes, Paris

2023-11-16

Recruiting

Anatomical-Clinical Base of Adenocarcinoma Pancreatic

NCT06128343Adenocarcinoma, Carcinoma, Neoplasms

University Hospital, Toulouse

Observational

1,500

Béthune, Bordeaux, Lille, Lyon, Montpellier, Pau, Toulouse

2023-11-16

Active, closed

Effect of a Health Pathway for People With Persistent Symptoms Covid-19

NCT05787366COVID-19

Centre Hospitalier Universitaire de Saint Etienne

Not applicable

400

Lyon, Saint-Etienne

2023-11-15

Recruiting

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

NCT06128551Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma

DrugsElironrasib·Cetuximab

Revolution Medicines, Inc.

Phase 1/2

534

Angers, Bordeaux, Bron, Lille, Lyon, Montpellier, Nantes, Strasbourg

2023-11-14

Recruiting

HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies

NCT05658640Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory

DrugsTrametinib·Cytarabine·Dexamethasone·Cyclophosphamide

Princess Maxima Center for Pediatric Oncology

Phase 1/2

Bordeaux, Lille, Lyon, Marseille, Nantes, Paris

2023-11-14

Recruiting

FIH XON7 in Advanced/Metastatic Solid Tumors

NCT06154291Advanced Solid Tumor, Metastatic Cancer

Xenothera SAS

Phase 1/2

255

Bordeaux, Lyon, Suresnes, Toulouse

2023-11-14

Recruiting

Adapted Physical Activity in the Treatment of Anorexia:

NCT05477537Anorexia Nervosa

Fondation Santé des Étudiants de France

Not applicable

220

Lille, Lyon, Montpellier, Nantes, Paris, Saint-Etienne

2023-11-14

Recruiting

ACP-204 in Adults With Alzheimer's Disease Psychosis

NCT06159673Alzheimer's Disease Psychosis

DrugACP-204

ACADIA Pharmaceuticals Inc.

Phase 2/3

1,074

Bron, Colmar, Dijon, Limoges, Lyon, Paris, Rouen, Toulouse

2023-11-14

Active, closed

Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease

NCT06075706Steroid-refractory Acute Graft-versus-host Disease

DrugMC0518

medac GmbH

Phase 2

Bordeaux, La Tronche, Lille, Lyon, Marseille, Montpellier, Nantes, Paris

2023-11-13

Active, closed

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

NCT06073821CLL

DrugsSonrotoclax·Zanubrutinib·Obinutuzumab·Venetoclax

BeOne Medicines

Phase 3

652

Bordeaux, ClermontFerrand, Esseylesnancy, Le Mans, Lille, Lyon, Nantes, Paris

2023-11-11

Active, closed

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

NCT06097728Unresectable Pleural Mesothelioma

DrugsVolrustomig·Yervoy·Paraplatin·Ipilimumab

AstraZeneca

Phase 3

863

Brest, Créteil, Le Mans, Lille, Lyon, Marseille, Montpellier, Paris

2023-11-09

Active, closed

Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial

NCT05999604Multiple Sclerosis

DrugOcrelizumab

Fondation Ophtalmologique Adolphe de Rothschild

Phase 3

244

Créteil, Gonesse, Grenoble, Limoges, Lyon, Nice, Paris, Poissy

2023-11-09

Active, closed

Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT

NCT05983198Prostate Cancer

Novartis Pharmaceuticals

Phase 1

Dijon, Clermont-Ferrand, Lyon, Nantes, Saint-Herblain, Vandœuvre-lès-Nancy

2023-11-07

Recruiting

A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

NCT06095089Prostatic Neoplasms

DrugsJNJ-101556143·JNJ-87189401·Lutetium Lu 177 vipivotide tetraxetan·Pasritamig

Janssen Research & Development, LLC

Phase 1

355

Bordeaux, Lyon, Villejuif

2023-11-01

Active, closed

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

NCT05987332Metastatic Uveal Melanoma

DrugsDarovasertib·Crizotinib·Dacarbazine·Yervoy

IDEAYA Biosciences

Phase 2/3

420

Lyon, Paris

2023-10-31

Recruiting

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

NCT05696626Metastatic Breast Cancer

DrugsAbemaciclib·Fulvestrant

LeonaBio

Phase 3

600

Avignon, Besançon, Bordeaux, Caen, Le Mans, Lille, Lyon, Marseille

2023-10-31

Recruiting

Hypnosis: a Path to Appeasement

NCT05942885Hematologic Cancer

Hospices Civils de Lyon

Not applicable

Lyon

2023-10-30

Recruiting

Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

NCT05918302Neuroendocrine Tumors, Lung Neuroendocrine Neoplasm, Thymus Neoplasms

Drugs177Lu-edotreotide·Everolimus

Grupo Espanol de Tumores Neuroendocrinos

Phase 3

170

Dijon, Bourdeaux, Lille, Lyon, Marseille, Montpellier, Nantes, Paris

2023-10-27

Recruiting

Endo-epicardial vs Endocardial-only Catheter Ablation of Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy (EPIC-VT)

NCT05888662Ischemic Cardiomyopathy, Catheter Ablation of Ventricular Tachycardia

Rennes University Hospital

Not applicable

150

Bordeaux, Caen, Clermont-Ferrand, Lille, Lyon, Nantes, Paris, Rennes

2023-10-23

Recruiting

Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy

NCT05840562Chemotherapy-induced Peripheral Neuropathy

DrugsCapsaicin·Duloxetine

Institut Cancerologie de l'Ouest

Phase 3

274

Angers, Bordeaux, Caen, Grenoble, Limoges, Lyon, Nantes, Nice

2023-10-20

Recruiting

Outpatient Laparoscopic Radical Prostatectomy

NCT05975775Prostate Cancer

GCS Ramsay Santé pour l'Enseignement et la Recherche

Observational

Lyon

2023-10-20

Recruiting

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

NCT06026410Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)

DrugsAdagrasib·Cabozantinib

Kura Oncology, Inc.

Phase 1

300

Lyon, Paris, Toulouse

2023-10-18

Active, closed

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

NCT05968326Adenocarcinoma, Pancreatic Ductal

DrugsAutogene Cevumeran·MFOLFIRINOX·Tecentriq·Atezolizumab

Genentech, Inc.

Phase 2

260

Lille, Lyon, Marseille, Vandœuvre-lès-Nancy, Villejuif

2023-10-18

Recruiting

Post-Market Clinical Follow Up for Total Knee Arthroplasty System Madison

NCT06120023Knee Arthropathy

Societe dEtude, de Recherche et de Fabrication

Observational

1,000

Lyon

2023-10-17

Active, closed

Evaluation of the Impact of an Expert Opinion During the Management of Patients With Severe Bleeding on Oral Anticoagulants.

NCT05928091Hemorrhage

University Hospital, Clermont-Ferrand

Not applicable

1,000

Aurillac, Clermont-Ferrand, Grenoble, Le Puy-en-Velay, Lyon, Montbrison, Montluçon, Moulins

2023-10-16

Recruiting

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

NCT06012240Alopecia Areata

DrugUpadacitinib

AbbVie

Phase 3

1,500

Nice, Rennes, Bordeaux, Toulouse, Reims, Nantes, Lyon, Brest

2023-10-11

Active, closed

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

NCT05257083Multiple Myeloma

DrugsCilta-cel·Bortezomib·Daratumumab·Lenalidomide

Stichting European Myeloma Network

Phase 3

759

Lille, Lyon, Nantes, Poitiers, Saint-Louis, Toulouse

2023-10-10

Recruiting

Fluid Responsiveness Prediction During Prone Position

NCT05898269Acute Respiratory Distress Syndrome

Hospices Civils de Lyon

Not applicable

Clermont-Ferrand, Lyon, Nice

2023-10-06

Active, closed

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

NCT05952557Breast Cancer, Early Breast Cancer

DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole

AstraZeneca

Phase 3

5,511

Angers, Bordeaux, Caen, Clermont-Ferrand, Dijon, Epagny Metz-Tessy, Lille, Lyon

2023-10-05

By invitation

A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

NCT06044337Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

DrugLitifilimab

Biogen

Phase 3

306

Caen, Toulouse, Montpellier, Lyon, Paris

2023-10-03

Recruiting

Screening for Abdominal Aortic Aneurysms in the General Practice by Ultraportable Ultrasound

NCT05617326Abdominal Aortic Aneurysm

Fondation Ophtalmologique Adolphe de Rothschild

Not applicable

400

Lyon, Paris

2023-10-02

Active, closed

Community Intervention to Eliminate HCV Among People Who Use Drugs.

NCT05794646HCV, Substance Use Disorders

ANRS, Emerging Infectious Diseases

Not applicable

3,400

Lyon, Marseille, Paris

2023-10-02

Recruiting

Short- and Medium-term Evaluation of Mastoid Filling Using Bioactive Glass"

NCT05921643Cholesteatoma

Centre Hospitalier Intercommunal Creteil

Observational

Lyon

2023-09-29

Recruiting

Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination

NCT05945524Multiple Myeloma

University Hospital, Toulouse

Not applicable

100

Amiens, Caen, Dijon, Epagny Metz- Tessy, Lille, Lyon, Montpellier, Paris

2023-09-28

Recruiting

Single-center Comparative Study of Variation in Acetabular Anteversion According to Pelvic Tilt in Patients With Femoro-acetabular Impingement and Healthy Volunteers.

NCT05678894Femoro-acetabular Impingement

GCS Ramsay Santé pour l'Enseignement et la Recherche

Not applicable

140

Lyon

2023-09-28

Active, closed

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

NCT06088290Leiomyosarcoma

DrugsLurbinectedin·Doxorubicin

PharmaMar

Phase 3

469

Lyon, Besançon, Angers, Nice, Bordeaux, Lille, Limoges, Marseille

2023-09-21

Active, closed

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

NCT06047080Large B-Cell Lymphoma

DrugsPolatuzumab Vedotin·Glofitamab·Doxorubicin·Prednisone

Hoffmann-La Roche

Phase 3

1,130

Lille, Lyon, Marseille, Montpellier, Nantes, Pessac, Rennes, Rouen

2023-09-18

Recruiting

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT05730036Relapsed Refractory Multiple Myeloma (RRMM)

DrugsElotuzumab·Linvoseltamab·Pomalidomide·Dexamethasone

Regeneron Pharmaceuticals

Phase 3

410

Lyon, Pessac, Lille, Paris, Saint-Cloud, Villejuif

2023-09-18

Recruiting

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

NCT06051617Primary Biliary Cholangitis

DrugSeladelpar

Gilead Sciences

Phase 3

402

Bobigny, Lille, Lyon, Montipellier, Paris, Strasbourg, Vandœuvre-lès-Nancy, Villejuif

2023-09-07

Recruiting

The ReTAVI Prospective Observational Registry

NCT05601453Structural Valve Deterioration, Structural Valve Degeneration, Symptomatic Patients Who Have Had Transcatheter Heart Valve (THV) Failure, Prosthetic Valve Malfunction

Institut für Pharmakologie und Präventive Medizin

Observational

250

Bordeaux, Clermont-Ferrand, Lille, Lyon, Marseille, Massy, Nantes, Paris

2023-09-05

Recruiting

CF Organization of Care in the Era of Highly Effective Modulator.

NCT06599892Cystic Fibrosis

Hospices Civils de Lyon

Observational

5,000

Lyon

2023-09-01

Active, closed

A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

NCT05884398Metastatic Castrate-sensitive Prostate Cancer

DrugApalutamide

Janssen Research & Development, LLC

Phase 3

420

Bordeaux, Lyon, Paris, Rennes, Villejuif

2023-08-31

Recruiting

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

NCT06051409Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive

DrugOlverembatinib

Ascentage Pharma Group Inc.

Phase 3

350

Le Chesnay, Lyon, Nantes, Nice, Pessac, Pierre-Bénite, Poitiers, Toulouse

2023-08-31

Recruiting

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

NCT06016842Primary Biliary Cholangitis (PBC)

DrugElafibranor

Ipsen

Phase 3

276

Clichy, Créteil, Lille, Lyon, Marseille, Nice, Paris, Poitiers

2023-08-31

Active, closed

Combination of PRP and XLHA Prepared With RegenMatrix Medical Device To Treat Moderate to Severe Knee Osteoarthritis

NCT05727371Knee Osteoarthritis

RegenLab France SAS

Not applicable

280

Dijon, Corbeil-Essonnes, Créteil, La Roche-sur-Yon, Limoges, Lyon, Montpellier, Nantes

2023-08-21

Recruiting

Haemostatic Gel Prophylaxis for Post Duodenal Endoscopic Resection Bleeding

NCT05746884Duodenal Bleeding

GCS Ramsay Santé pour l'Enseignement et la Recherche

Not applicable

234

Lyon

2023-08-21

Recruiting

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

NCT05875168Advanced Solid Tumor, Metastatic Solid Tumor

Daiichi Sankyo

Phase 1/2

590

Lyon, Marseille, Saint-Herblain, Strasbourg, Toulouse, Villejuif

2023-08-18

Recruiting

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

NCT05803941Prostate Cancer

DrugLu-PSMA

Novartis Pharmaceuticals

Phase 4

700

Lyon

2023-08-14

Active, closed

SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate Cancer

NCT05826509Prostate Cancer

Institut Claudius Regaud

Phase 2

240

Angers, Bordeaux, Créteil, Grenoble, Lille, Lyon, Marseille, Paris

2023-08-10

Active, closed

The BD Liverty™ TIPS Stent Graft Study

NCT05711316Portal Hypertension, TIPS

C. R. Bard

Not applicable

177

Chambray-lès-Tours, Dijon, Lyon

2023-08-08

Recruiting

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

NCT05983432Non Small Cell Lung Cancer, Esophageal Cancer, Small Cell Lung Cancer, Nasopharyngeal Cancer

DrugIza-bren

SystImmune Inc.

Phase 1

540

Lyon, Paris, Saint-Herblain, Villejuif

2023-08-08

Recruiting

Study Comparing Negative Pressure Dressing vs Conventional in Patients With Resected STS After Radiotherapy

NCT05944913Soft Tissue Sarcoma

Centre Leon Berard

Not applicable

166

Nantes, Lyon, Angers, Bordeaux, Chambray-lès-Tours, Clermont-Ferrand, Dijon, Lille

2023-08-03

Recruiting

Aspirin for the Prevention of Preeclampsia and Pregnancy Outcomes After Assisted Reproductive Technology

NCT05625724ART, Pre-Eclampsia

DrugAspirin

University Hospital, Toulouse

Phase 3

1,164

Angers, Bordeaux, Clermont-Ferrand, Dijon, Lille, Lyon, Marseille, Montpellier

2023-08-02

Recruiting

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

NCT05855200Colonic Neoplasms, Neoplasms, Colon

DrugsCapeox·Dostarlimab·Folfox

GlaxoSmithKline

Phase 3

892

Lyon, Marseille, Nantes, Paris, Pessac, Rennes, Rouen, Saint-Priest-en-Jarez

2023-08-01

Recruiting

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

NCT05967689Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

DrugZipalertinib

Taiho Oncology, Inc.

Phase 2

220

Strasbourg, Lyon, Caen, Limoges, Pessac, Marseille, Saint-Herblain, Boulogne-Billancourt

2023-07-31

Active, closed

Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy

NCT05949593Geographic Atrophy

DrugTinlarebant

Belite Bio, Inc

Phase 3

429

Dijon, Écully, Lyon, Marseille

2023-07-27

Active, closed

Predictors of Anterior Patellofemoral Pain After Anterior Cruciate Ligament Reconstruction

NCT06185803Anterior Cruciate Ligament Reconstruction

GCS Ramsay Santé pour l'Enseignement et la Recherche

Observational

500

Lyon

2023-07-27

Recruiting

PREventing Second Cancers With DOSTARlimab

NCT05855811Recurrent Cancer, Primary Cancer, Second Cancer

DrugDostarlimab

Centre Leon Berard

Phase 2

400

Caen, Clermont-Ferrand, Lyon, Toulouse, Villejuif

2023-07-26

Active, closed

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

NCT05843643Systemic Lupus Erythematosus

DrugUpadacitinib

AbbVie

Phase 3

1,014

Toulouse, Lyon, Paris

2023-07-25

Recruiting

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

NCT05836324Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors

DrugsINCA33890·ADG126·Folfox·Cetuximab

Incyte Corporation

Phase 1

570

Lyon, Villejuif

2023-07-24

Recruiting

GastrOesophageal Tumor, Immune Microenvionnment (GOTIM)

NCT05644431GastroEsophageal Cancer

Centre Leon Berard

Observational

Lyon

2023-07-19

Recruiting

Same Day Ambulatory Appendectomy (SAMBA)

NCT05691348Appendicitis

Centre Hospitalier Universitaire de Nice

Not applicable

1,400

Nice, Bordeaux, Troyes, La Tronche, Lyon, Saint-Priest-en-Jarez, Voiron, Marseille

2023-07-17

By invitation

A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study

NCT05777993Pyruvate Kinase Deficiency, Anemia, Hemolytic, Sickle Cell Disease, Thalassemia

DrugMitapivat

Agios Pharmaceuticals, Inc.

Phase 4

Marseille, Bordeau, Créteil, Lyon, Paris

2023-07-06

Active, closed

A Study of Zigakibart in Adults With IgA Nephropathy

NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy

DrugZigakibart

Novartis Pharmaceuticals

Phase 3

383

Nîmes, Lille, Lyon, Grenoble, Paris

2023-07-06

Recruiting

Complications in Pediatric Mechanical Circulatory Assistance: Evaluation of Infection Management.

NCT06464016Heart-Assist Devices, Infections, Heart Transplant Infection

Claude Bernard University

Observational

Lyon

2023-07-04

Recruiting

Human Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients

NCT05843786Pneumonia, Ventilator-Associated

Hospices Civils de Lyon

Phase 3

132

Limoges, Lyon, Nancy, Paris, Pierre-Bénite, Saint-Etienne

2023-06-30

Recruiting

Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders

NCT05136976Anti-MAG Neuropathy

DrugRituximab

Centre Hospitalier Universitaire de Saint Etienne

Phase 3

Brest, Grenoble, Lille, Limoges, Lyon, Marseille, Nancy, Nantes

2023-06-29

Active, closed

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT05878769Chronic Obstructive Pulmonary Disease

DrugAstegolimab

Hoffmann-La Roche

Phase 3

2,000

Amiens, Lyon, Marseille, Nice, Pessac, Strasbourg

2023-06-28

Active, closed

Casting Light on HOst-cytomegaloviRUs Interaction in Solid Organ Transplantation

NCT05701228Cytomegalovirus Infections, Solid Organ Transplantation

University Hospital, Bordeaux

Observational

552

Bordeaux, Lyon, Paris, Suresnes, Toulouse, Villejuif

2023-06-26

Recruiting

IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

NCT05742607Non Small Cell Lung Cancer

DrugDurvalumab

Innate Pharma

Phase 2

Angers, Caen, Lille, Limoges, Lyon, Marseille, Rennes, Rouen

2023-06-23

Active, closed

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

NCT05889182Hidradenitis Suppurativa

DrugUpadacitinib

AbbVie

Phase 3

1,328

Nice, Bordeaux, Reims, Nantes, Lyon, Antony

2023-06-21

Recruiting

Implementation of REFOCUS Training Program in Mental Health Services

NCT05824234Mental Disorders

Hôpital le Vinatier

Not applicable

760

Lyon

2023-06-19

Active, closed

Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma

NCT05830084Ewing Sarcoma

DrugRegorafenib

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1

Bordeaux, Lille, Lyon, Paris, Villejuif

2023-06-16

Recruiting

A Research Registry on Aggressive PitNETs

NCT05974696Endocrine Tumor

Hospices Civils de Lyon

Observational

200

Lyon

2023-06-15

Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

NCT05646862Breast Cancer

DrugsBupropion·Omeprazole·Alpelisib·Inavolisib

Hoffmann-La Roche

Phase 3

420

Avignon, Bayonne, Bordeaux, Lyon, Montpellier, Rennes, Toulouse

2023-06-07

Active, closed

Real-Life Evaluation of the HA Dermal Filler ESTYME® LIFT

NCT07385053Nasolabial Folds, Wrinkles

Symatese

Not applicable

Arras, Lyon

2023-06-05

Recruiting

RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.

NCT05758831Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis

Rennes University Hospital

Phase 3

386

Lyon, Brest, Caen, Cergy-Pontoise, Clermont-Ferrand, Gonesse, Lille, Limoges

2023-06-01

Active, closed

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

NCT05607550Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations

DrugFurmonertinib

ArriVent BioPharma, Inc.

Phase 3

398

Caen, Lyon, Marseille, Toulouse, Villejuif

2023-06-01

Recruiting

A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

NCT05862285Cancer

DrugsTiragolumab and Atezolizumab·Divarasib·Tiragolumab·Ipatasertib

Hoffmann-La Roche

Phase 3

100

Marseille, Bordeaux, Caen, Dijon, Lyon, Montpellier, Nantes, Nîmes

2023-06-01

Active, closed

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

NCT05740566Small Cell Lung Cancer (SCLC)

DrugsAmrubicin·Lurbinectedin·Tarlatamab·Topotecan

Amgen

Phase 3

509

Grenoble, Lille, Limoges, Lyon, Marseille, Paris, Pierre-Bénite, Rennes

2023-05-31

Recruiting

A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

NCT05765851Advanced Solid Tumor

DrugTrastuzumab deruxtecan

Daiichi Sankyo

Phase 1

128

Lyon, Toulouse

2023-05-30

Recruiting

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

NCT05732831Locally Advanced Solid Tumor

DrugsTNG462·Keytruda·Pembrolizumab

Tango Therapeutics, Inc.

Phase 1/2

225

Brest, Lyon, Saint-Herblain, Villejuif

2023-05-26

Recruiting

Comparison of EVAR and ESAR for Infrarenal Aortic Aneurysms With a Wide Proximal Neck

NCT05484115Aortic Aneurysm, Abdominal

Rijnstate Hospital

Not applicable

300

Lyon, Marseille, Nîmes

2023-05-26

Active, closed

EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)

NCT06923761Advanced Solid Malignancy

Grey Wolf Therapeutics

Phase 1/2

300

Lyon, Marseille, Rennes, Saint-Herblain, Strasbourg, Toulouse, Villejuif

2023-05-21

Recruiting

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

NCT05895786Myositis

Pfizer

Phase 3

318

Lyon, Paris, Reims, Strasbourg

2023-05-20

Active, closed

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

NCT05663866Carcinoma, Non-Small-Cell Lung

DrugsMontelukast·Lazertinib·Amivantamab·Methotrexate

Janssen Research & Development, LLC

Phase 2

Brest, Lyon, Paris, Rouen, Strasbourg

2023-05-18

Recruiting

Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment

NCT05580861Acute Myeloid Leukemia

DrugSulfasalazine

Assistance Publique - Hôpitaux de Paris

Phase 1/2

Amiens, Bobigny, Caen, Créteil, Lyon, Marseille, Nice, Paris

2023-05-17

Recruiting

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

NCT05748171ACUTE LYMPHOBLASTIC LEUKEMIA

DrugInotuzumab Ozogamicin

Pfizer

Phase 2

100

Nice, Strasbourg, Bordeaux, Toulouse, Vandœuvre-lès-Nancy, Lille, Paris, Lyon

2023-05-17

Recruiting

Study of the Impact of Mother-of-pearl Nutritional Supplementation on the Prevention of Post-menopausal Osteoporosis

NCT05571514Post Menopausal Osteoporosis

Centre Hospitalier Universitaire de Saint Etienne

Not applicable

200

Clermont-Ferrand, Grenoble, Le Puy-en-Velay, Lyon, Paris, Roanne, Saint-Etienne

2023-05-12

Recruiting

Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer

NCT05462613Metastatic Colorectal Cancer

DrugsRegorafenib·Aspirin·Folfox·Bevacizumab

Centre Hospitalier Universitaire de Besancon

Phase 2/3

446

Besançon, Clermont-Ferrand, Créteil, Dijon, Lyon, Montbéliard, Montpellier, Mulhouse

2023-05-09

Active, closed

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

NCT05840211Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer

DrugsAbraxane·Xeloda·Sacituzumab Govitecan·Taxol

Gilead Sciences

Phase 3

654

Besançon, Bordeaux, Dijon, Lille, Limoges, Loire Atlantique, Lyon, Marseille

2023-05-08

Active, closed

Phase III Study of AK112 for NSCLC Patients

NCT06396065Non-Squamous Non-small Cell Lung Cancer

DrugsIvonescimab·Pemetrexed·Carboplatin

Summit Therapeutics

Phase 3

420

Créteil, Lyon, Paris, Villejuif

2023-05-04

Active, closed

An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma

NCT05876754Cholangiocarcinoma

DrugIvosidenib

Servier Affaires Médicales

Phase 3

299

Lyon, Marseille, Montpellier, Nantes, Paris, Pessac, Poitiers

2023-05-03

Recruiting

Cohort of STEMI Patients 2

NCT05794022Myocardial Infarction

DrugBiocollection

Hospices Civils de Lyon

Not applicable

300

Bron, Lyon

2023-05-03

Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

NCT05800665Advanced Prostate Cancer, Metastatic Prostate Cancer

Genentech, Inc.

Phase 1

210

Villejuif, Lyon, Marseille

2023-05-02

Recruiting

Evaluation of the Impact of a Paramedical Training Program for Nurses and Nursing Assistants on the Length of Stay and Prevention of Hospital Iatrogenic Complications in Elderly Patients

NCT05936515Iatrogenesis

Hospices Civils de Lyon

Observational

2,671

Bourg-en-Bresse, Lyon, Metz-Tessy, Pierre-Bénite, Villefranche-sur-Saône

2023-05-01

Recruiting

OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial

NCT05587894COVID-19, Immunodeficiency

DrugsNirmatrevlir/ritonavir·Veklury·Remdesivir

ANRS, Emerging Infectious Diseases

Phase 2

256

Bordeaux, Dijon, Lyon, Montpellier, Nantes, Paris, Reims, Toulouse

2023-04-27

By invitation

An Open-label Study of XEN1101 in Epilepsy

NCT05718817Focal Epilepsy, Tonic-Clonic Seizures

DrugAzetukalner

Xenon Pharmaceuticals Inc.

Phase 3

880

Lyon, Paris, Rennes, Strasbourg

2023-04-25

Active, closed

Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients

NCT05705973Cardiovascular Disease, Coronary Artery Occlusion, Ischemic Heart Disease

Terumo Europe N.V.

Observational

3,000

Besançon, Bron, Essey-lès-Nancy, Lyon, Massy, Nîmes, Rouen, Suresnes

2023-04-25

Recruiting

Impact of a Physical Activity Intervention With Motivational Support From Peers for Prostate Cancer Patients

NCT05739565Prostate Cancer

Centre Hospitalier Universitaire de Saint Etienne

Not applicable

850

Chambéry, Clermont-Ferrand, Grenoble, Le Puy-en-Velay, Lyon, Privas, Roanne, Saint-Etienne

2023-04-25

Active, closed

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

NCT05805501Renal Cell Carcinoma

DrugsTobemstomig·Tiragolumab·Axitinib·Keytruda

Hoffmann-La Roche

Phase 2

199

Avignon, Besançon, Bordeaux, Caen, Lyon, Villejuif

2023-04-21

Recruiting

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

NCT05768139Breast Cancer, Solid Tumors, Adult

DrugsTersolisib·Imlunestrant·Tamoxifen·Exemestane

Eli Lilly and Company

Phase 1/2

880

Bordeaux, Lyon, Marseille, Nice, Toulouse, Villejuif

2023-04-17

Active, closed

A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

NCT05645692Urothelial Cancer

DrugsTobemstomig·Tiragolumab·Atezolizumab

Hoffmann-La Roche

Phase 2

204

Lyon, Villejuif

2023-04-13

Recruiting

ProActIF-01 Trial: Feasibility Study of an Individualized Program of Nutrition and Adapted Physical Activity in Frail Patients With Advanced Digestive Cancers

NCT05441163CANCER

Institut Curie

Not applicable

Tours, Avignon, Bordeaux, Clermont-Ferrand, Grenoble, Lille, Lyon, Montpellier

2023-04-08

Recruiting

Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic Telangiectasia

NCT05641142Hereditary Hemorrhagic Telangiectasia, Rendu Osler Disease

University Hospital, Clermont-Ferrand

Not applicable

100

Angers, Bordeaux, Boulogne-Billancourt, Caen, Clermont-Ferrand, Dijon, Lille, Lyon

2023-04-07

Active, closed

A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis

NCT05785611Axial Spondyloarthritis

DrugFilgotinib

Alfasigma S.p.A.

Phase 3

495

Boulogne-Billancourt, Lyon, Orléans, Pierre-Bénite, Rouen

2023-04-05

Active, closed

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma

NCT05692180Asthma

DrugBenralizumab

AstraZeneca

Phase 3

Créteil, Lyon, Rouen

2023-04-05

Active, closed

Efficacy Study on Quality of Life Criteria of a Digital Application on Any Cellphone (OnKO-Tips&Tricks) for Adolescents and Young Adults Diagnosed With Cancer

NCT05350631Cancer

University Hospital, Strasbourg, France

Not applicable

200

Lyon, Nantes, Nice, Reims, Strasbourg, Marseille, Rennes, Saint-Herblain

2023-04-04

Active, closed

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies

NCT05794906Biochemically Recurrent Prostate Cancer

DrugDarolutamide

Bayer

Phase 3

985

Clermont-Ferrand, La Tronche, Lyon, Pierre-Bénite, Besançon, Dijon, Brest, Rennes

2023-04-03

Recruiting

NAlmefene Versus Placebo in Addition to Treatment as Usual on Craving in Behavioural Addictions

NCT05540288Behavioural Addiction

Nantes University Hospital

Phase 3

266

Besançon, Bordeaux, Brest, Clermont-Ferrand, Dijon, La Rochelle, Lyon, Montpellier

2023-03-31

Recruiting

A Multicentre French Prospective Study of Children With Food Protein Induced Enterocolitis Syndrome in Its Acute Form

NCT05528900Food Protein Induced Enterocolitis Syndrome (FPIES)

Fondation Lenval

Not applicable

600

Angers, Aulnay-sous-Bois, Clermont-Ferrand, Colmar, Grenoble, Haguenau, Lille, Lyon

2023-03-31

Recruiting

Intensive Preoperative Speech Rehabilitation in Drug-Resistant Temporal Epilepsy

NCT05609084Epilepsy, Anomia, Temporal Lobe Epilepsy

Assistance Publique Hopitaux De Marseille

Not applicable

214

Bordeaux, Grenoble, Lille, Lyon, Marseille, Nancy, Paris, Rennes

2023-03-30

Active, closed

Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI

NCT05601973Non Small Cell Lung Cancer

DrugsLazertinib·Zirabev·Amivantamab

ETOP IBCSG Partners Foundation

Phase 2

Angers, Avignon, Lyon

2023-03-27

Recruiting

Interest of a Highly Cross-linked Polyethylene Acetabular Component Doped With Vitamin E in Total Hip Arthroplasty of the Young and Active Subject

NCT05175300Hip Arthropathy

GCS Ramsay Santé pour l'Enseignement et la Recherche

Not applicable

100

Lyon

2023-03-24

Active, closed

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

NCT05714202Bladder Cancer

DrugsTAR-200·Cetrelimab

Janssen Research & Development, LLC

Phase 3

1,135

Bordeaux, Clermont-Ferrand, Grenoble, Limoges, Lyon, Nantes, Nîmes, Orléans

2023-03-23

Recruiting

Prospective, Longitudinal, Observational Registry of Adult Patients With Hypophosphatasia (REG-HYPO)

NCT05596539Hypophosphatasia

Assistance Publique - Hôpitaux de Paris

Observational

200

Bordeaux, Lille, Lyon, Nice, Paris, Poitiers, Rennes, Saint-Priest-en-Jarez

2023-03-22

Recruiting

Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification

NCT05259605Glioma, Glioneuronal Tumor, Choroid Plexus Tumor, Pineal Tumors

European Organisation for Research and Treatment of Cancer - EORTC

Observational

1,650

Lyon, Marseille, Paris

2023-03-21

Active, closed

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

NCT05650879HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification

DrugsELVN-002·Fam-Trastuzumab Deruxtecan-Nxki·Trastuzumab emtansine·Trastuzumab deruxtecan

Enliven Therapeutics

Phase 1

198

Marseille, Rennes, Caen, Bordeaux, Dijon, Lyon, Villejuif

2023-03-20

Recruiting

Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence

NCT05310591B Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse

Assistance Publique - Hôpitaux de Paris

Phase 1/2

Bordeaux, Lille, Lyon, Marseille, Montpellier, Nancy, Nantes, Paris

2023-03-15

Active, closed

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

NCT05445778Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer

DrugsMirvetuximab Soravtansine·Bevacizumab

AbbVie

Phase 3

520

Strasbourg, Marseille, Dijon, Brest, Lyon, Paris

2023-03-15

Recruiting

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

NCT05706129Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Urothelial Carcinoma (UC)

Lumara Bio Oncologics GmbH

Phase 1/2

270

Clermont-Ferrand, Dijon, Grenoble, Lyon, Marseille, Nantes, Toulouse, Vandœuvre-lès-Nancy

2023-03-14

Active, closed

Symptoms Control and adhErenCe Assessment During Treatment With MepolizUmab New pREfilled Devices

NCT05626777Asthma

Hospices Civils de Lyon

Phase 4

Besançon, Dijon, Lille, Lyon, Montpellier, Paris, Reims, Toulouse

2023-03-09

Recruiting

Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations

NCT06511648Muscle-invasive Bladder Cancer

DrugErdafitinib

Spanish Oncology Genito-Urinary Group

Phase 2

Clermont-Ferrand, Lyon, Paris, Toulouse, Villejuif

2023-03-07

Recruiting

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

NCT05677971Alpha1-Antitrypsin Deficiency

DrugFazirsiran

Takeda

Phase 3

160

Clichy, Lyon, Pessac, Rennes, Toulouse, Val-de-Marne

2023-03-06

Recruiting

Cost-utility of Focal HIFU vs Prostatectomy

NCT05710861Prostate Cancer

University Hospital, Bordeaux

Not applicable

346

Besançon, Bordeaux, Colmar, Grenoble, Guilherand-Granges, Lille, Lyon, Marseille

2023-03-06

Recruiting

Monitoring of the End-tidal Carbon Dioxide (EtCO2) as a Severity Criterion in COPD Exacerbations

NCT05704881Pulmonary Disease, Chronic Obstructive, Exacerbation Copd

University Hospital, Grenoble

Observational

240

Grenoble, Lyon

2023-03-03

Active, closed

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

NCT05566795Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma

DrugsTovorafenib·Carboplatin

Day One Biopharmaceuticals, Inc.

Phase 3

418

Lille, Lyon, Marseille, Paris, Villejuif

2023-02-27

Active, closed

Study With Various Immunotherapy Treatments in Participants With Lung Cancer

NCT05676931Advanced Non-Small Cell Lung Cancer

DrugsQuemliclustat·Domvanalimab·Zimberelimab·Docetaxel

Gilead Sciences

Phase 2

400

Bordeaux, Lyon, Strasboug, Suresnes

2023-02-21

Recruiting

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

NCT05667142Primary Generalized Tonic-Clonic Seizures

DrugAzetukalner

Xenon Pharmaceuticals Inc.

Phase 3

160

Lille, Lyon, Paris, Rennes, Strasbourg

2023-02-14

Active, closed

Evaluation of the Efficacy of HIFU Treatment on Rectal Endometriosis Symptoms.

NCT05755958Endometriosis

EDAP TMS S.A.

Not applicable

Aix-en-Provence, Angers, Bordeaux, Clermont-Ferrand, Le Kremlin-Bicêtre, Lille, Lyon, Paris

2023-02-03

Recruiting

PHAGEinLYON Clinic Cohort Study: a Descriptive Study of Severe Infections Treated With Phage Therapy at the HCL.

NCT06185920Severe Infection

Hospices Civils de Lyon

Observational

250

Lyon

2023-02-01

Recruiting

Avis-PHAGEinLYON Clinic

NCT05883995Bone Infection

Hospices Civils de Lyon

Observational

1,500

Lyon

2023-02-01

Recruiting

Clinical Data Collection of Patients Treated With High Intensity Focused Ultrasound (HIFU) by the Focal One for Their Prostate Cancer.

NCT07645872Prostate Cancer

EDAP TMS S.A.

Observational

3,000

Aix-en-Provence, Besançon, Colmar, Lyon, Nantes

2023-02-01

Not yet open

Biomarker-s of Abusive Head Trauma by Proteomics

NCT05626465Abuse, Child, Protein Disorder, Blood

University Hospital, Geneva

Observational

174

Lyon

2023-02

Recruiting

Characterization of the Intrahepatic Inflammatory Microenvironment in Patients With Non-alcoholic Steatohepatitis

NCT06152250Liver Diseases

Hospices Civils de Lyon

Not applicable

Lyon

2023-01-29

Active, closed

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer

NCT05563220Breast Cancer, Metastatic Breast Cancer

DrugsAlpelisib·Capivasertib·Elacestrant·Everolimus

Stemline Therapeutics, Inc.

Phase 1/2

435

Lyon, Montpellier, Rouen, Toulouse, Villejuif

2023-01-24

Active, closed

OFSEP Very High Definition Cohort

NCT05622643Multiple Sclerosis

EDMUS Foundation

Observational

300

Lyon, Nancy, Nîmes, Rennes, Strasbourg

2023-01-19

Recruiting

A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease

NCT06198712Sickle Cell Disease

DrugEtavopivat

Forma Therapeutics, Inc.

Phase 2

Lyon, Paris, Roeun

2023-01-12

Recruiting

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

NCT05614739Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms

DrugsVepugratinib·Digoxin·Enfortumab Vedotin·Rosuvastatin

Eli Lilly and Company

Phase 1

677

Bordeaux, Lyon, Villejuif

2023-01-12

Active, closed

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

NCT05555732Metastatic Non Small Cell Lung Cancer

DrugsDato-DXd·Pemetrexed·Keytruda·Cisplatin

Daiichi Sankyo

Phase 3

1,170

Avignon, Besançon, Bordeaux, France, Lyon, Marseille, Montpellier, Nantes

2023-01-11

Active, closed

First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

NCT05527184Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer

DrugIMGN151

AbbVie

Phase 1

256

Saint-Herblain, Nice, Lyon, Pierre-Bénite, Villejuif

2023-01-11

Active, closed

Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1

NCT05680818Autosomal Dominant Hypocalcemia (ADH)

DrugEncaleret

Calcilytix Therapeutics, Inc., a BridgeBio company

Phase 3

Le Kremlin-Bicêtre, Lyon

2023-01-06

Active, closed

NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies

NCT05605496Advanced Solid Tumors, Metastatic Solid Tumors

DrugNP137

Centre Leon Berard

Phase 2

Lyon, Nice, Paris, Strasbourg, Toulouse

2023-01-06

Active, closed

Evaluation of a New Navigation System in Computer-assisted Total Knee Arthroplasty

NCT05435690Gonarthrosis

GCS Ramsay Santé pour l'Enseignement et la Recherche

Not applicable

126

Lyon

2023-01-06

Recruiting

Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial

NCT05378347Abdominal Aortic Aneurysm, Abdominal Aortic Aneurysm >= 5.5 Centimeters in Male (Disorder), Abdominal Aortic Aneurysm >= 5.0 Centimeters in Female (Disorder)

Medtronic Cardiovascular

Not applicable

600

Marseille, Clermont-Ferrand, Lyon, Strasbourg

2023-01-05

Active, closed

Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

NCT05678673Non-Clear Cell Renal Cell Carcinoma

DrugsSunitinib Malate·Zanzalintinib·Sunitinib·Opdivo

Exelixis

Phase 3

317

Angers, Caen, Clermont-Ferrand, Créteil, Le Mans, Lille, Lyon, Marseille

2023-01-01

Recruiting

Retrospective and Prospective Follow-up of Patients With Primary Hyperoxaluria Type 1 Treated With Lumasiran in France.

NCT06225882Patients With PH1 Treated With Lumasiran in France

Hospices Civils de Lyon

Observational

100

Besançon, Bron, Lyon, Marseille, Paris

2023-01-01

Recruiting

Personalized Tidal Volume in ARDS (VT4HEMOD)

NCT05406570Acute Respiratory Distress Syndrome

Hospices Civils de Lyon

Not applicable

Lyon

2022-12-29

Recruiting

Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation

NCT04935684Acute Leukemia in Remission, Myelodysplastic Syndromes, Myeloproliferative Syndrome, Hodgkin Lymphoma

DrugFecal Microbiota Transplantation

University Hospital, Clermont-Ferrand

Phase 2

150

Amiens, Angers, Besançon, Clermont-Ferrand, Grenoble, Lille, Limoges, Lyon

2022-12-20

Recruiting

Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours

NCT05752552Adult Solid Tumor, Advanced Solid Tumor, Refractory Tumor, Non-small Cell Lung Cancer

DeuterOncology

Phase 1

Bordeaux, Lille, Lyon, Marseille, Nice, Rennes, Villejuif

2022-12-20

Recruiting

Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas

NCT05751798Solid Advanced Tumor, Lymphoma, NSCLC (Non-small Cell Lung Cancer)

OSE Immunotherapeutics

Phase 1/2

Lyon, Paris, Rennes, Saint-Herblain, Toulouse, Villejuif

2022-12-20

Recruiting

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

NCT05640999Endometrial Cancer

Canadian Cancer Trials Group

Phase 2

393

Lyon, Villejuif, Lille, Toulouse, Paris

2022-12-19

Recruiting

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

NCT05549297Advanced Melanoma

DrugTebentafusp

Immunocore Ltd

Phase 3

540

Lyon, Toulouse, Villejuif, Bordeaux, Marseille, Paris

2022-12-19

Recruiting

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

NCT05232916Breast Cancer

Greenwich LifeSciences, Inc.

Phase 3

2,250

Avignon, Brest, Caen, Chambray-lès-Tours, Cholet, Contamine-sur-Arve, Lyon, Nantes

2022-12-16

Recruiting

Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

NCT05327894Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia

DrugBlinatumomab

Princess Maxima Center for Pediatric Oncology

Phase 3

160

Amiens, Besançon, Bordeaux, Grenoble, Lille, Lyon, Marseille, Montpellier

2022-12-15

Recruiting

Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

NCT05631249KRAS P.G12C, Non Small Cell Lung Cancer

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2

Lyon, Marseille, Paris, Villejuif

2022-12-13

Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

NCT05633654Triple Negative Breast Cancer

DrugsXeloda·Sacituzumab Govitecan·Keytruda·Capecitabine

Gilead Sciences

Phase 3

1,514

Amiens, Chambray-lès-Tours, Dijon, Le Mans, Limoges, Loire Atlantique, Lyon, Nancy

2022-12-12

Active, closed

Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)

NCT04968106Resectable Sarcoma

DrugsRetifanlimab·Ifosfamide·Doxorubicin

Institut Bergonié

Phase 2

Bordeaux, Lyon, Paris

2022-12-07

Recruiting

CIRculating CANcer MAster-Protocol

NCT05089747Adult With Solid Cancer

Hospices Civils de Lyon

Observational

6,000

Bron, Lyon, Pierre-Bénite

2022-12-05

Recruiting

Impact of a Multidisciplinary End-of-treatment Day Hospital on the Quality of Life of Adolescents and Young Adults With Cancer

NCT05858424Solid Tumor, Lymphoma

Centre Leon Berard

Not applicable

214

Lyon

2022-11-29

Active, closed

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

NCT05629585Breast Cancer

DrugsDato-DXd·Xeloda·Durvalumab·Keytruda

AstraZeneca

Phase 3

1,174

Angers, Bordeaux, Dijon, Lyon, Montpellier, Nîmes, Paris, Poitiers

2022-11-28

Active, closed

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)

NCT05456191Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

DrugsAsciminib·ABL001·Nilotinib

Novartis Pharmaceuticals

Phase 3

568

Bordeaux, Caen, Clermont-Ferrand, Lille, Lyon, Marseille, Nantes, Nice

2022-11-21

Recruiting

Evaluation of the Efficacy of Azithromycin in Idiopathic Purulent Oedematous Sinusitis in Adults

NCT05157685Sinusitis, Chronic, Sinus Infection Chronic

DrugAzithromycin

Centre Hospitalier Intercommunal Creteil

Phase 3

230

Bordeaux, Créteil, Le Kremlin-Bicêtre, Lille, Lyon, Marseille, Nancy, Nantes

2022-11-21

Active, closed

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

NCT05476926Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion

DrugsVabysmo·Faricimab

Hoffmann-La Roche

Observational

6,000

Strasbourg, Marseille, Dijon, Bordeaux, Nantes, Saint-Étienne-de-Montluc, Lyon, Rouen

2022-11-21

Recruiting

Optimized Rehabilitation After Anterior Cruciate Ligament Before Returning to Sport

NCT05323474Ligament Knee Injury, Anterior Cruciate Ligament Rupture

Centre Hospitalier Universitaire de Saint Etienne

Not applicable

432

Challes-les-Eaux, Domont, Firminy, Lyon, Saint-Etienne

2022-11-14

Recruiting

Impact of the Presence of Anti-interferon Autoantibodies on the Viral Load in Severe Respiratory Infections

NCT05536219Severe Respiratory Infections

Hospices Civils de Lyon

Observational

360

Bron, Pierre-Bénite, Lyon

2022-11-08

Active, closed

A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)

NCT05170204Non-Small Cell Lung Cancer

DrugsEntrectinib·Alectinib·Durvalumab

Hoffmann-La Roche

Phase 3

Caen, Lyon, Marseille

2022-11-01

Active, closed

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

NCT05544929Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial

DrugsKeytruda·Pembrolizumab

Novartis Pharmaceuticals

Phase 1

126

Lyon

2022-10-26

Recruiting

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

NCT05552222Multiple Myeloma

DrugsTalquetamab·Teclistamab·Daratumumab·Lenalidomide

Janssen Research & Development, LLC

Phase 3

1,590

Créteil, Lille, Lyon, Nantes, Paris, Pessac, Poitiers, Rennes

2022-10-25

Recruiting

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

NCT05253651Colorectal Neoplasms

DrugsTucatinib·Herceptin·Erbitux·Avastin

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

400

Besançon, Avignon, Brest, Clermont-Ferrand, Créteil, Dijon, Lyon, Marseille

2022-10-24

Active, closed

A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer

NCT05587296Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes

Bayer

Phase 3

474

Lyon, Strasbourg, Bordeaux, Caen, Montpellier, Angers, Saint-Herblain, Paris

2022-10-14

Active, closed

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

NCT05455320Multiple Myeloma

DrugsTalquetamab·Pomalidomide·Daratumumab·Dexamethasone

Janssen Research & Development, LLC

Phase 3

864

Créteil, Dijon, Lyon, Montpellier, Nantes, Nice, Paris, Pessac

2022-10-13

Active, closed

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

NCT05206357Non-hodgkin Lymphoma

DrugEpcoritamab

Genmab

Phase 1

Bordeaux, Nantes, Villejuif, Lyon

2022-10-04

Recruiting

Met Non Small Cell Cancer Registry (MOMENT)

NCT05376891Cancer

EMD Serono Research & Development Institute, Inc.

Observational

700

Cholet, Lille, Lorient, Lyon, Paris, Rennes, Toulouse

2022-10-04

Recruiting

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

NCT05183035Acute Myeloid Leukemia

DrugsGemtuzumab Ozogamicin·Cytarabine·Azacitidine·Fludarabine

PedAL BCU, LLC

Phase 3

130

Toulouse, Loos, Nantes, Lyon, Paris

2022-10-01

Recruiting

A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies

NCT05443126NSCLC

DrugPemetrexed

Ellipses Pharma

Phase 1/2

265

Bordeaux, Caen, Lyon, Marseille, Paris

2022-09-30

Recruiting

INSIGHTFUL-FFR Clinical Trial

NCT05437900Coronary Artery Disease, Acute Coronary Syndrome

CoreAalst BV

Phase 4

2,500

Lille, Lyon, Paris

2022-09-22

Active, closed

CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

NCT05440786Sarcoma, Ewing, Neoplasm Metastasis

DrugsAbemaciclib·Temozolomide·Irinotecan

Eli Lilly and Company

Phase 2

Bordeaux, Lyon

2022-09-20

Active, closed

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

NCT05462717Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor

DrugElironrasib

Revolution Medicines, Inc.

Phase 1

222

Angers, Bordeaux, Clermont-Ferrand, Lille, Lyon, Nantes, Strasbourg

2022-09-19

Active, closed

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

NCT05450692Advanced or Metastatic Non-Small Cell Lung Cancer

DrugsCeralasertib·Durvalumab·Docetaxel

AstraZeneca

Phase 3

594

Angers, Clamart, Clermont-Ferrand, Créteil, Lyon, Montpellier, Nantes, Paris

2022-09-15

Recruiting

Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)

NCT05384821Wilms Tumor

DrugsTemozolomide·Vincristine·Irinotecan·Etoposide

Centre Oscar Lambret

Phase 1/2

Amiens, Besançon, Bordeaux, Grenoble, Lille, Lyon, Marseille, Montpellier

2022-09-14

Active, closed

XIENCE Skypoint Large Vessel Post Approval Study

NCT05423379Coronary Artery Disease

Abbott Medical Devices

Observational

102

Toulouse, Lyon

2022-09-14

Active, closed

Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer

NCT05425940Colorectal Cancer

DrugsZanzalintinib·Regorafenib·Tecentriq·Atezolizumab

Exelixis

Phase 3

901

Besançon, Dijon, Herbault, Lyon, Marseille, Paris, Suresnes

2022-09-07

Recruiting

De-escalation Study for Stage IIa/IIb < 3 cm Seminoma

NCT05529251Seminoma, Stage II

DrugCarboplatin AUC7

Centre Leon Berard

Phase 2

Besançon, Bordeaux, Caen, Clermont-Ferrand, Lille, Limoges, Lyon, Marseille

2022-09-06

Recruiting

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

NCT05489211Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer

DrugsPrednisone/Prednisolone·Volrustomig·Rilvegostomig·Dato-DXd

AstraZeneca

Phase 2

454

Bordeaux, Lyon, Marseille, Suresnes

2022-09-06

Recruiting

Evaluate DF-003 in ex Vivo Assays Using Peripheral Blood Mononuclear Cell From Subjects With ROSAH Syndrome

NCT05319132Unrecognized Condition

Hospices Civils de Lyon

Observational

Lyon, Angers, Paris, Reims, Rennes

2022-09-06

Active, closed

Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis

NCT04074096Malignant Melanoma, BRAF V600 Mutation, Brain Metastases

DrugsBinimetinib·Encorafenib·Keytruda·Pembrolizumab

UNICANCER

Phase 2

Bobigny, Bordeaux, Boulogne-Billancourt, Caen, Créteil, Dijon, Lyon, Marseille

2022-09-05

By invitation

Outcome of Patients With Severe Functional TR According to Medical, Transcatheter or Surgical Treatment

NCT05825898Tricuspid Regurgitation

Ottawa Heart Institute Research Corporation

Observational

3,500

Amiens, Créteil, Lille, Lyon, Marseille, Nancy, Nantes, Paris

2022-09-01

Recruiting

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

NCT05386108Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms

DrugsElacestrant·Abemaciclib

Stemline Therapeutics, Inc.

Phase 1/2

Angers, Brest, Caen, Clermont-Ferrand, Lyon, Montpellier, Paris, Poitiers

2022-08-31

Active, closed

Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

NCT04711135Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma

DrugsLutetium [177Lu] oxodotreotide/dotatate·Lutathera

Advanced Accelerator Applications

Phase 2

Lyon

2022-08-31

Recruiting

Asciminib Roll-over Study

NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib

Novartis Pharmaceuticals

Phase 4

347

Bordeaux, Lyon, Marseille, Nantes, Paris, Vandœuvre-lès-Nancy

2022-08-30

Recruiting

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

NCT05548296Endometrial Adenocarcinoma

DrugGemcitabine

Acrivon Therapeutics

Phase 2

350

Caen, Lyon, Saint-Herblain, Villejuif

2022-08-29

Active, closed

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

NCT05500222NASH, Cirrhosis, Liver

DrugResmetirom

Madrigal Pharmaceuticals, Inc.

Phase 3

845

Lyon, Vandœuvre-lès-Nancy, Lille, Clichy, Créteil, Nice, Paris, Strasbourg

2022-08-26

Active, closed

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT05361395Extensive Stage Small Cell Lung Cancer

DrugsTarlatamab·Tecentriq·Etoposide·Atezolizumab

Amgen

Phase 1

184

Lyon, Saint-Herblain, Villejuif

2022-08-24

Active, closed

Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]

NCT05536973Neovascular Age-related Macular Degeneration

Adverum Biotechnologies, Inc.

Phase 2

Nantes, Lyon, Créteil

2022-08-23

Recruiting

Variations of Immune Infiltrate and Cell Plasticity Markers in Treated Metastatic Melanoma Patients

NCT05029791Melanoma

Hospices Civils de Lyon

Not applicable

100

Lyon

2022-08-18

Active, closed

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

NCT05327530Locally Advanced or Metastatic Urothelial Carcinoma

DrugsAvelumab·Sacituzumab Govitecan

EMD Serono Research & Development Institute, Inc.

Phase 2

256

Suresnes, Angers, Bordeaux, Caen, Créteil, Le Mans, Lyon, Marseille

2022-08-17

Recruiting

A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

NCT05463263Lymphoma, B-Cell, Lymphoma, T-Cell

DrugSTP938

Step Pharma, SAS

Phase 1/2

180

Paris, Lyon, Marseille, Nantes, Villejuif

2022-08-03

Active, closed

Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis

NCT05297448Hepatic Encephalopathy

DrugRifaximin SSD

Bausch Health Americas, Inc.

Phase 3

466

Angers, Belfort, Besançon, Clermont-Ferrand, Limoges, Lyon, Nice, Paris

2022-08-03

Recruiting

A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

NCT05410145KRAS P.G12C

DrugsD3S-001·Cetuximab·Pemetrexed·Cisplatin

D3 Bio (Wuxi) Co., Ltd

Phase 1/2

442

Bordeaux, Lyon, Rennes, Villejuif

2022-08-03

Active, closed

First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

NCT05489237Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases

DrugIDRX-42

IDRX, Inc., a wholly owned subsidiary of GSK, LLC

Phase 1

276

Bordeaux, Lyon, Marseille, Villejuif

2022-08-03

Active, closed

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382286Triple Negative Breast Cancer, PD-L1 Positive

DrugsAbraxane·Sacituzumab Govitecan·Taxol·Nab-paclitaxel

Gilead Sciences

Phase 3

443

Avignon, Besançon, Bordeaux, Brest, Caen, Clermont-Ferrand, Lyon, Marseille

2022-07-25

Recruiting

Evaluation Patient Satisfaction After Passive Bladder Catheter Removal Compared to Active Removal

NCT05313945Urologic Diseases

Hospices Civils de Lyon

Not applicable

160

Grenoble, Lyon

2022-07-21

Recruiting

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)

NCT04165486Multiple System Atrophy

Ionis Pharmaceuticals, Inc.

Phase 1

Lyon, Paris, Toulouse

2022-07-21

Recruiting

Evaluation of the Statistical Validity of Cervical Spine Measurements-Including Range of Motion, Strength, and Functional Test Results-for Return to Sport in Patients Who Have Undergone Surgery for Cervical Stenosis and/or Herniation.

NCT07886112Cervical Stenosis, Cervical Spine

GCS Ramsay Santé pour l'Enseignement et la Recherche

Not applicable

Lyon

2022-07-19

Active, closed

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

NCT05296798Locally Advanced or Metastatic Breast Cancer

DrugsGiredestrant·Phesgo·Pertuzumab·Trastuzumab

Hoffmann-La Roche

Phase 3

922

Avignon, Bayonne, Besançon, Bordeaux, Grenoble, La Roche-sur-Yon, Lyon, Paris

2022-07-18

Active, closed

Assess Safety and Efficacy of VAD044 in HHT Patients

NCT05406362Hereditary Hemorrhagic Telangiectasia (HHT)

DrugEngasertib

Vaderis Therapeutics AG

Phase 1/2

Lyon

2022-07-18

Active, closed

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

NCT05126277Lupus Nephritis

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

452

Besançon, Bordeaux, Grenoble, Lyon, Marseille, Poitiers, Toulouse, Vandœuvre-lès-Nancy

2022-07-14

Active, closed

Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase)

NCT05164055Glycogen Storage Disease Type II

DrugAvalglucosidase alfa

Genzyme, a Sanofi Company

Phase 4

Bordeaux, Brest, Clermont-Ferrand, Lille, Lyon, Marseille, Nantes, Nice

2022-07-11

Active, closed

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

NCT05338970Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion

DrugPatritumab deruxtecan

Daiichi Sankyo

Phase 3

586

Brest, Caen, Lyon, Montpellier, Paris, Pierre-Bénite, Rennes, Saint-Herblain

2022-07-08

Active, closed

Study of INCB123667 in Subjects With Advanced Solid Tumors

NCT05238922Solid Tumors

DrugsRibociclib·Palbociclib·Olaparib·Fulvestrant

Incyte Corporation

Phase 1

291

Bordeaux, Lyon, Toulouse, Villejuif

2022-07-05

Recruiting

Profiling Program of Advanced/Metastatic Pancreatic Cancer Patients

NCT05380414Metastatic Pancreatic Cancer, Advanced Pancreatic Cancer

Centre Leon Berard

Not applicable

750

Lyon

2022-07-01

Active, closed

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

NCT05364073Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, HER2 Exon 20 Mutations

DrugFurmonertinib

ArriVent BioPharma, Inc.

Phase 1

160

Lyon, Toulouse, Villejuif

2022-06-30

Active, closed

Laparoscopic Inguinal and Femoral heRniA rePaIr Using Pre-shapeD 4DMESH® (4DLap)

NCT05306496Inguinal Hernia, Femoral Hernia

Cousin Biotech

Not applicable

196

Lyon, Nantes, Reims, Tourcoing

2022-06-30

Recruiting

RhEumatoid Arthritis MEDIcation Adherence

NCT05413759Rheumatoid Arthritis

Hospices Civils de Lyon

Not applicable

200

Pierre-Bénite, Lyon

2022-06-28

Recruiting

Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.

NCT05378204Breast Cancer

Institut Claudius Regaud

Not applicable

120

Bordeaux, Caen, Clermont-Ferrand, Dijon, La Roche-sur-Yon, Lille, Limoges, Lyon

2022-06-23

Recruiting

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

NCT05429632Adult Acute Myeloid Leukemia

Priothera SAS

Phase 3

366

Angers, Lille, Lyon, Nancy, Nantes, Paris, Strasbourg, Toulouse

2022-06-16

Active, closed

A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies

NCT05329766Gastrointestinal Tract Malignancies

DrugsQuemliclustat·Domvanalimab·Zimberelimab·Fluorouracil

Arcus Biosciences, Inc.

Phase 2

332

Bordeaux, Brest, Caen, Lille, Lyon, Marseille, Montpellier, Plérin

2022-06-10

Recruiting

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

NCT05384626Locally Advanced Solid Tumor, Metastatic Solid Tumor

DrugsNeladalkib·Repaglinide·Itraconazole·Midazolam

Nuvalent Inc.

Phase 1/2

840

Lyon, Nantes, Toulouse, Villejuif

2022-06-09

Recruiting

Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma

NCT04894370Squamous Cell Anal Carcinoma, Metastatic Squamous Cell Carcinoma

DrugSample collection

Centre Hospitalier Universitaire de Besancon

Phase 2

Besançon, Dijon, Levallois-Perret, Lyon, Montbéliard

2022-06-09

Recruiting

A Study of ASP3082 in Adults With Advanced Solid Tumors

NCT05382559Solid Tumor

DrugsNanoparticle Albumin-Bound Paclitaxel·Setidegrasib·Liposomal Irinotecan·Fluorouracil

Astellas Pharma Inc

Phase 1

681

La Tronche, Bordeaux, Lyon, Villejuif

2022-06-08

Recruiting

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

NCT05365581Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma

DrugsASP2138·Ramucirumab·Fluorouracil·Leucovorin

Astellas Pharma Global Development, Inc.

Phase 1

398

Vaillant, Lyon, Marseille, Poitiers, Saint-Herblain, Toulouse

2022-06-07

Recruiting

Assessment of Cardiac Coherence Associated With Medical Hypnosis on Preoperative Anxiety in Oncological Surgery

NCT05197972Surgery, Oncology

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

296

Montpellier, Lyon, Toulouse, Villejuif

2022-06-01

Recruiting

Survival of Monocytes Collected From Patients With Atrophic AMD in Retinal Pigmented Epithelium Explants

NCT04697095Age Related Macular Degeneration

Hospices Civils de Lyon

Not applicable

Lyon

2022-06-01

Active, closed

An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration

NCT05300724Age-Related Macular Degeneration

Genentech, Inc.

Observational

400

Créteil, Écully, Grenoble, Lyon, Strasbourg

2022-05-27

Active, closed

PASS of Paediatric Patients Initiating Selumetinib

NCT05388370Neurofibromatosis Type 1

AstraZeneca

Observational

124

Amiens, Angers, Bordeaux, Lille, Lyon, Marseille, Paris, Rennes

2022-05-23

Recruiting

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

NCT05304377Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml

DrugELVN-001

Enliven Therapeutics

Phase 1

250

Amiens, Bordeaux, Lille, Limoges, Lyon, Pierre-Bénite

2022-05-22

Active, closed

Biomarkers in Multiple Myeloma

NCT05259553Hematological Patients, Newly Diagnosed Multiple Myeloma, Chemotherapy

Centre Hospitalier Universitaire de Saint Etienne

Not applicable

Lyon, Saint-Etienne

2022-05-20

Recruiting

Evaluation of Safe Use of SECURIDRAP® SELFIA®

NCT05510401Disorientation, Cognitive Impairment, Behavior Disorders

Groupe Mulliez-Flory

Not applicable

108

Bailleul, Bully-les-Mines, Hazebrouck, Le Quesnoy, Lille, Limoux, Lyon, Rennes

2022-05-18

Active, closed

Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults

NCT05210413Refractory or Recurrent Solid Tumor

University Hospital, Bordeaux

Phase 1/2

Angers, Bordeaux, Lille, Lyon, Marseille, Nantes, Paris, Strasbourg

2022-05-17

Recruiting

Evaluation of Two Surgical Strategies for Robotic Implantation of Total Knee Prostheses (Stryker), Cemented Versus Uncemented

NCT04692714Total Knee Arthroplasty

Hospices Civils de Lyon

Not applicable

200

Lyon

2022-05-16

Active, closed

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

NCT05374512Breast Cancer

DrugsEribulin·Dato-DXd·Nab-paclitaxel·Capecitabine

AstraZeneca

Phase 3

644

Bordeaux, Dijon, Limoges, Lyon, Marseille, Montpellier, Paris, Rouen

2022-05-16

Active, closed

A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

NCT05307705Breast Cancer

DrugsAnastrozole, Exemestane·Imlunestrant·Abemaciclib·Letrozole

Eli Lilly and Company

Phase 1

260

Lyon, Paris, Saint-Herblain, Strasbourg, Villejuif

2022-05-11

Recruiting

Phage Safety Cohort Study

NCT04650607Prosthetic Joint Infection, Severe Infection

Hospices Civils de Lyon

Observational

100

Lyon

2022-05-09

Recruiting

Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC

NCT05310643Metastatic Colorectal Cancer

DrugsYervoy·Ipilimumab·Opdivo·Nivolumab

GERCOR - Multidisciplinary Oncology Cooperative Group

Phase 2

Besançon, Bordeaux, Lille, Limoges, Lyon, Montpellier, Nice, Paris

2022-05-05

Recruiting

PROton Versus Photon Therapy for Esophageal Cancer - a Trimodality Strategy

NCT05055648Esophageal Cancer, Radiotherapy, Side Effect, Proton Therapy

University of Aarhus

Phase 3

396

Lyon, Nice, Paris

2022-05-01

Recruiting

Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas

NCT05182164Soft Tissue Sarcoma Adult, Advanced Soft-tissue Sarcoma, Ewing Sarcoma, Osteosarcoma

DrugCabozantinib

Institut Bergonié

Phase 2

119

Bordeaux, Dijon, Lille, Lyon, Marseille, Paris, Saint-Herblain, Toulouse

2022-04-25

By invitation

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab

NCT05303532Cancer

DrugDurvalumab

AstraZeneca

Phase 3

214

Besançon, Bordeaux, Brest, Dijon, Lyon, Marseille, Montpellier, Rennes

2022-04-19

Active, closed

HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas

NCT05180695Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma

DrugsSiremadlin·Pazopanib

Centre Leon Berard

Phase 1/2

Bordeaux, Lyon, Marseille, Toulouse, Villejuif

2022-04-15

Recruiting

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

NCT05208047Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer

DrugsBezuclastinib·Sunitinib·Midazolam

Cogent Biosciences, Inc.

Phase 3

482

Bordeaux, Lille, Lyon, Marseille, Rennes, Saint-Herblain, Toulouse, Villejuif

2022-04-14

Active, closed

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

NCT05288166Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs

DrugsAbiraterone·Abemaciclib·Prednisolone·Prednisone

Eli Lilly and Company

Phase 3

925

Lyon, Brest, La Chaussée-Saint-Victor, Dijon, Besançon, Montpellier, Nantes, Saint-Herblain

2022-04-14

Recruiting

Randomized Double Blind Controlled Trial Comparing the Safety and Efficacy of Apremilast Versus Placebo in Severe Forms of Recurrent Aphthous Stomatitis

NCT04227314Recurrent Aphtous Stomatitis

DrugApremilast

University Hospital, Rouen

Phase 3

134

Amiens, Bobigny, Bordeaux, Brest, Créteil, Le Mans, Lille, Lyon

2022-04-10

Recruiting

Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors

NCT04068155Skin Cancer, Cutaneous Tumor, Cutaneous Metastasis

Alpha Tau Medical LTD.

Not applicable

Grenoble, Lyon

2022-04-01

Recruiting

A Study Comparing the Effectiveness of EndoRotor Versus Radiofrequency in Treating Barrett's Esophagus

NCT04867590Barrett Esophagus, Dysplasia

University Hospital, Angers

Not applicable

140

Besançon, Brest, Chambray-lès-Tours, Dijon, Lille, Limoges, Lyon, Montpellier

2022-03-25

Recruiting

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT04928846Non Small Cell Lung Cancer, c-MET

DrugsTelisotuzumab vedotin·Docetaxel

AbbVie

Phase 3

768

Marseille, Lille, Montpellier, Pessac, Paris, Avignon, Bron, Lyon

2022-03-25

Active, closed

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

NCT05239728Carcinoma, Renal Cell

DrugsBelzutifan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

1,800

Lyon, Strasbourg, Rennes, Chambray-lès-Tours, Besançon, Angers, Paris, Villejuif

2022-03-15

Active, closed

Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

NCT05280470Extensive-stage Small-cell Lung Cancer

DrugIfinatamab Deruxtecan

Daiichi Sankyo

Phase 2

187

Créteil, Lyon, Marseille, Montpellier, Paris

2022-03-09

Active, closed

LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB

NCT05210621Multiple Sclerosis

DrugOcrelizumab

Centre Hospitalier Universitaire de Nice

Phase 3

Amiens, Bayonne, Bordeaux, Caen, Clermont-Ferrand, Lille, Lyon, Marseille

2022-03-08

Recruiting

Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia

NCT05246345Chronic Lymphocytic Leukemia, CLL, Progressive Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia

University Hospital, Clermont-Ferrand

Observational

Amiens, Besançon, Bobigny, Clermont-Ferrand, Grenoble, Lille, Lyon, Montpellier

2022-03-07

Active, closed

AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma

NCT04881032Glioblastoma

DrugTemozolomide

Centre Jean Perrin

Phase 1/2

Brest, Clermont-Ferrand, Grenoble, Lyon, Paris, Saint-Herblain, Strasbourg, Villejuif

2022-03-07

Active, closed

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

NCT05215340Metastatic Non Small Cell Lung Cancer

DrugsDato-DXd·Keytruda·Pembrolizumab

Daiichi Sankyo

Phase 3

740

Avignon, Bordeaux, Lille, Lyon, Marseille, Montpellier, Nantes, Paris

2022-03-04

Recruiting

Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects

NCT04775706Short Bowel Syndrome

Hanmi Pharmaceutical Company Limited

Phase 2

Clichy, Bordeaux, Lyon, Nice

2022-03-03

Active, closed

Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma

NCT04874311Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma

DrugsBintrafusp alfa·Doxorubicin

Institut Bergonié

Phase 2

Bordeaux, Dijon, Lyon, Marseille, Paris, Poitiers

2022-03-01

Active, closed

Chronic Pain and Hemophilia

NCT05202951Chronic Pain, Hemophilia

University Hospital, Clermont-Ferrand

Observational

350

Bordeaux, Caen, Chambéry, Clermont-Ferrand, Grenoble, Lille, Lyon, Nantes

2022-02-28

Recruiting

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

NCT04988555Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes

DrugsAzoles·Gilteritinib·Azacitidine·Venetoclax

Sumitomo Pharma America, Inc.

Phase 1/2

606

Angers, Bobigny, Le Mans, Lille, Limoges, Lyon, Marseille, Nantes

2022-02-28

Recruiting

Evaluation of Percutaneous Cryotherapy in the Treatment of Plexiform Neurofibromas and Unresectable Neurofibromas in Neurofibromatosis Type 1

NCT05199376Neurofibroma, Neurofibroma, Plexiform

Centre Leon Berard

Not applicable

Lyon

2022-02-14

Active, closed

A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)

NCT04573023Mucopolysaccharidosis II

DrugsIdursulfase·JR-141

JCR Pharmaceuticals Co., Ltd.

Phase 3

Lyon, Montpellier, Paris

2022-02-14

Active, closed

Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer

NCT05486182Metastatic Breast Cancer

GE Healthcare

Phase 4

153

Dijon, La Tronche, Limoges, Lyon, Montpellier, Neuilly-sur-Seine, Nice, Paris

2022-02-08

Recruiting

Characterization of Immune-response in Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes

NCT05772611Autoimmune Encephalitis, Paraneoplastic Neurological Syndrome

Hospices Civils de Lyon

Observational

180

Lyon

2022-02-01

Active, closed

ADH1 and ADH2 Disease Monitoring Study (DMS)

NCT05227287Autosomal Dominant Hypocalcemia

Calcilytix Therapeutics, Inc., a BridgeBio company

Observational

Bron, Lyon, Lille, Le Kremlin-Bicêtre

2022-01-20

Recruiting

Prospective Multicenter Study Evaluating Feasibility and Efficacy of Tumor Organoid-based Precision Medicine in Patients With Advanced Refractory Cancers

NCT05267912Advanced, Pretreated Solid Tumors

Gustave Roussy, Cancer Campus, Grand Paris

Not applicable

152

Bordeaux, Lille, Lyon, Paris, Poitiers, Reims, Rennes, Saint-Mandé

2022-01-19

Recruiting

Clariance ErYs Registry

NCT05170815Spine Degeneration, Spine Spondylosis Thoracic, Spinal Deformity, Spinal Tumor

Clariance

Observational

760

Lyon

2022-01-17

Active, closed

New Biomarkers in Auto-immune Encephalitis and Neurological Paraneoplastic Syndromes

NCT05728931Paraneoplastic Neurological Syndrome, Autoimmune Encephalitis

Hospices Civils de Lyon

Observational

210

Lyon

2022-01-15

Active, closed

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

NCT05002127Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma

DrugsEvorpacept·Ramucirumab·Herceptin·Taxol

ALX Oncology Inc.

Phase 2/3

127

Besançon, Bordeaux, Brest, Lyon, Marseille, Paris, Toulouse

2022-01-15

Active, closed

A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments

NCT05152472Unresectable Gastrointestinal Stromal Tumor (GIST), Locally Advanced Gastrointestinal Stromal Tumor (GIST), Metastatic Gastrointestinal Stromal Tumor

DrugsGlivec·Imatinib·Tecentriq·Atezolizumab

Centre Leon Berard

Phase 2

Lyon, Bordeaux, Lille, Marseille, Nice, Poitiers, Reims, Rennes

2022-01-14

Active, closed

LVIS™ Evo™ and HydroCoil® Embolic System for Intracranial Aneurysm Treatment

NCT04999423Intracranial Aneurysm

Microvention-Terumo, Inc.

Observational

206

Brest, Limoges, Lyon, Marseille, Paris, Rouen

2022-01-14

Active, closed

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD

DrugsEylea·Aflibercept

AbbVie

Phase 3

735

Nice, Lyon, Dijon, Toulouse, Paris, Nantes, Marseille, Créteil

2022-01-13

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a French investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 October 2026. https://priyalifescience.com/clinical-trials-france/city/lyon?page=2

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in France and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,697 studies in total at the last sync on 26 Oct 2026, 03:20 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,392 of those studies with a site in Lyon.

How many clinical trials are recruiting in Lyon?

784 of the 1,392 studies on this page are recruiting new participants as of the 26 Oct 2026, 03:20 UTC sync. A further 143 have not yet opened recruitment, 449 are active but closed to new participants, and 16 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.